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CHARACTERIZATION AND TARGET IDENTIFICATION OF NON-TOXIC IKKβ
INHIBITORS FOR ANTICANCER THERAPY
Elizabeth C. Blowers Ph.D.
University of Nebraska, 2015

Advisor: Amarnath Natarajan, Ph.D.
IKKβ is a key kinase in the canonical NF-κB pathway. Transient activation of IKKβ
is required for normal immune response while sustained activation has been implicated in
cancer. To date, no IKKβ inhibitor has been approved for clinical use as a
chemotherapeutic, likely due to unexpected toxicities associated with blocking the
transient activation of IKKβ. We hypothesized that an IKKβ inhibitor that allows transient
activation of IKKβ, but not sustained activation of IKKβ, could inhibit cancer growth without
inducing toxicity.
As such, we identified a small molecule inhibitor, 13-197, that allows the transient
activation of IKKβ but not the sustained activation of IKKβ. 13-197 inhibits cancer growth
without inducing toxicity. Structure activity relationship studies (SAR) were conducted with
13-197 analogs to determine substituents key for activity against IKKβ-mediated NF-κB
activity and the anticancer effects of 13-197 were studied in pancreatic cancer cells. 13197 inhibited NF-κB pathway proteins and decreased the expression of anti-apoptotic
proteins.
To further explore options for the development of non-toxic IKKβ inhibitors, 25-4
was designed to feature the -methylene--butyrolactone targeting motif of the IKKβ and
NF-κB inhibitor parthenolide. Parthenolide is active against IKKβ and NF-κB in cell-based
studies but the drug has not been approved as an anticancer treatment despite its effects
in cells and lack of toxicity in clinical trials. SAR studies with 25-4 identified structural
features key to the small molecule’s activity and click chemistry with a 25-4 analog verified
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the molecule’s activity towards IKKβ and NF-κB. Cell-based studies with 25-4 demonstrate
the molecule’s anticancer activities, such as growth inhibition, inhibition of colony
formation and induction of apoptosis. Furthermore, 25-4 synergized with the clinical
chemotherapeutic cisplatin to inhibit the viability of cancer cells. Future studies will
elucidate the mechanistic basis for non-toxic inhibition of IKKβ by 25-4 and will focus on
improving the drug-like properties of the small molecule.
Overall, these studies demonstrate that IKKβ is a viable target for anticancer
treatment and establish 13-197 and 25-4 as novel inhibitors of IKKβ with IC50s comparable
to

known

IKKβ

chemotherapeutics.

inhibitors

and

synergistic

activity

with

clinically-relevant
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Chapter 1: Background and Significance
Introduction to the NF-κB pathway
Nuclear factor kappa B (NF-κB) is a transcription factor that plays a key role in
innate and adaptive immune responses, inflammation, cell growth and apoptosis. This
pathway is activated by a myriad of stimuli such as tumor necrosis factor alpha (TNF),
interleukin 1 (IL-1), phorbol myristate acetate (PMA), ultraviolet radiation and stress to
name a few.1 In unstimulated cells, dimers of NF-κB are sequestered in the cytoplasm by
inhibitor of nuclear factor κB (IκB). In cells stimulated
with the pro-inflammatory cytokine TNF (Figure 1),
IκBs are phosphorylated by the inhibitor of κB kinase
(IKK) complex, polyubiquitinated, and degraded by
the 26S proteasome, allowing NF-κB dimers to enter
the nucleus and regulate transcription.2 The NF-κB
pathway controls the expression of hundreds of
genes, including genes encoding cytokines and
chemokines,

immunoreceptors,

acute

phase

proteins, cell adhesion molecules, regulators of
apoptosis and many transcription factors, among
others. The chemokines and cytokines regulated by
NF-κB include interferon gamma,3 many of the
interleukins4-7

and

TNF8

to

name

a

few.

Figure 1: TNF induces
IKKβ-mediated
NF-κBdriven transcription. Here,
NF-κB pathway activation is
driven
by
the
proinflammatory cytokine TNF
and leads to the transcription
of a κB DNA elementcontaining promoter.

Immunoreceptors include CD80, which is necessary
for co-stimulation of T cells,9, 10 IgG and IgE heavy chains11-13 and the immunoglobulin light
chain κ for which the transcription factor is named.14 The cell adhesion molecules
regulated by NF-κB include fibronectin,15 ICAM-116 and P-selectin.17 Acute phase proteins
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include LPS binding protein18 and complement factor C4, which activates the extrinsic
pathway of complement activation.19 Apoptotic genes controlled by NF-κB include both
pro-apoptotic and pro-survival proteins such as Bax,20 Bcl-xL,21 Bcl-222, Mcl-1,23 survivin,24
and X-linked inhibitor of apoptosis (XIAP).25 Important transcription factors regulated by
NF-κB include p53,26 c-myc,27 A20,28 c-fos,29 relb,30 c-rel,31 IκB,32 nfκB133 and 2.34 Many
of these transcription factors actually regulate the activity of NF-κB itself and serve to
negatively regulate the pathway’s activity. Though very abridged, the list of NF-κBregulated genes given above demonstrates the importance of the tight regulation of this
transcription factor in physiological and diseased states. As so many key processes are
controlled by this pathway, improper or chronic activation of the pathway results in many
diseases, including inflammatory diseases, immunodeficiency, autoimmunity and
cancer.35
The NF-κB family of proteins
The NF-κB family of proteins is comprised of five members including p65 (RelA),
RelB, c-Rel and NF-κB1 (p105) and NF-κB2 (p100), which are proteolytically processed
to p50 and p52, respectively. Each member of the family forms homo- or heterodimers
and share a Rel homology domain (RHD) which facilitates dimerization and binding to κB
DNA elements. In resting cells, p65, RelB and c-Rel are bound to the inhibitory IκBs, which
associate with the DNA-binding domains of the NF-κB family members and yield them
transcriptionally inactive. The pro-forms of p50 and p52, on the other hand, contain ankyrin
repeats similar to those in the IκBs that serve as inhibitors of nuclear translocation. Unlike
the other NF-κB family members, p50 and p52 lack transactivation domains and thus
serve as repressors of transcription unless bound to p65 or RelB.36 The domain
architecture of the prototypical NF-κB subunit p65 can be seen in Figure 2. Once free, NFκB dimers translocate to the nucleus where they may bind to promoter or enhancer regions
containing the κB consensus sequence 5′ GGGRNWYYCC 3′ (where N represents any

3
base, R represents any purine, W represents an adenine or thymine and Y represents a
pyrimidine). The κB site sequence, however, is quite degenerate and different NF-κB
dimers show binding preferences for different sites leading to transcription of particular
genes by specific dimers. The crystal structures of NF-κB dimers reveal that an Ig-like
domain located in the N-terminus of NF-κB is responsible for the selectivity towards
particular κB sites.37 Though 15 possible dimers have been shown to exist, the p50/p65
dimer is the most common dimer and is present in nearly all cell types.38
The IκB family of proteins
The IκB family of proteins contains six members including IκB, IκBβ, IκBε, IκBγ,

Figure 2: Domain structure of the prototypical members of the NF-κB, IκB, and
IKK families (top to bottom). The name of the protein is listed to the left and the
number of amino acids in the protein is listed on the right. Domains discussed in this
dissertation are listed. RHD, Rel homology domain; TA, transactivation; ANK,
ankyrin; PEST, proline, glutamate, serine and threonine-enriched domain; KD,
kinase domain; ULD, ubiquitin-like domain; SDD, scaffold and dimerization domain;
NBD, NEMO-binding domain; CC, coil coil domain; LZ, leucine zipper; and Z, zinc
finger. Adapted from references 41, 46
Bcl-3 (B-cell lymphoma 3) and IκBζ. IκB, IκBβ and IκBε are considered typical IκB
proteins (along with the precursor proteins p105 and p100, which can be grouped as NFκB or IκB family members) and serve to retain NF-κB dimers in the cytoplasm. Degradation
of the typical IκBs occurs once the protein has been phosphorylated on two serine
residues within the consensus sequence (DS∗GXXS∗) by the kinase IKKβ. For IκB,
which is the IκB that will be discussed in this dissertation, the phosphorylation occurs on
residues 32 and 36. This phosphorylation event leads to recognition by βTrCP proteins
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and K48-linked polyubiquitination by the Skp1-Culin-Roc1/Rbx1/Hrt-1-F-box family of E3
ligases (SCFβTrCP-E3 ligase complexes) and the E2 UbcH5 and subsequent degradation
in the 26S proteasome, which consequently allows NF-κB dimers to translocate to the
nucleus.37 Dimers composed of p65 and p50 are primarily associated with IκB. Structural
analysis of the complex composed of IκB, p65 and p50 revealed that IκB hides the
nuclear localization sequence (NLS) of p65 but does nothing to mask the NLS of p50.39, 40
As such, the balance between the NLS of p50 and the nuclear export sequence (NES) of
IκB results in shuttling of the complex between the nucleus and cytosol, though
localization of the complex appears to be cytosolic. IκB phosphorylation, ubiquitination
and degradation, however, shifts the equilibrium of the complex towards the nucleus by
eliminating the NES in IκB and exposing the NLS of p65.38 IκB is a better substrate for
IKKβ than IκBβ or IκBε resulting in its rapid degradation.41, 42
IκBβ and IκBε are degraded more slowly than IκB or not at all.41 Both IκBs are
degraded and resynthesized upon stimulation of the NF-κB pathway but their kinetics differ
from that of IκB and their roles in NF-κB signaling are still poorly understood. For example,
deletion of IκBβ has no effect on the kinetics of NF-κB signaling but knocking IκBβ in to
replace IκB also does not affect the kinetics of the pathway, suggesting that resynthesis
of the two proteins plays a major role in the cellular effects.43, 44
The atypical members of the IκB family include Bcl-3 and IκBζ and their roles are
still not well understood. Bcl-3 features a transactivation domain and has been found in
the nucleus in complex with p50 and p52 homo-dimers. In the case of p50, Bcl-3 may
relieve transcriptional repression by removing p50 homodimers from κB elements. On the
other hand, Bcl-3 may also stabilize p50 homodimers and prevent access of other TADcontaining NF-κB dimers to κB elements. With p52, Bcl-3 may potentiate transcriptional
activation, particularly of Cyclin D1. IκBζ is not constitutively expressed but is up-regulated
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in response to IL-1 and TLR4 ligands, but not TNF41 and thus will not be discussed at
length here.
As more data regarding the function of the IκB family members becomes available,
it is increasingly clear that these proteins can no longer be considered only inhibitors of
NF-κB signaling. Nevertheless, the main IκB discussed in this dissertation will be IκB and
its only important role for this work will be its binding to and prevention of translocation of
p65/p50-containing heterodimers.
The IKK complex and canonical (IKKβ-dependent) NF-κB signaling
The IKK complex is a 550-900 kDa complex composed of IKK (85 kDa), IKKβ (87
kDa), and IKKγ, which is also referred to as NEMO (48 kDa).45 The complex was originally
identified by immunoprecipitation and anion exchange chromatography of fractionated
whole cell extracts from HeLa cells that had been stimulated with TNF. IKK and IKKβ
were subsequently established as catalytic subunits while NEMO was determined to be a
regulatory subunit. IKK and IKKβ share 51% sequence identities and are highly
homologous in their kinase domains. A main structural difference between the two is the
presence of an ubiquitin like domain (ULD) on IKKβ that is not predicted in IKK.
Furthermore, IKK contains a nuclear localization sequence that is not present in IKKβ.
NEMO, on the other hand, is structurally unrelated to IKK and IKKβ and is composed of
two coil-coil domains, a leucine zipper, a zinc finger domain and a minimal oligomerization
domain (MOD) that may allow NEMO to oligomerize.1
Though it has not been conclusively proven and the discrepancy between the
molecular weights of the core components of the IKK complex and the observed molecular
weight of the purified complex has caused much debate over the years, it is currently
believed that the active IKK complex is composed of a tetramer of NEMO subunits that
brings an IKK/β heterodimer together.45 However, IKKβ activation of the NF-κB pathway
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in cells lacking IKK is clear evidence that homodimers also interact with NEMO.1 IKK
and IKKβ bind NEMO via a C-terminal NEMO binding domain (NBD). The regulation of
the kinase activity associated with the IKK complex is not fully understood. NEMO-induced
oligomerization is believed to induce a conformational change in IKK/β heterodimers.
IKK/β heterodimers are then activated by upstream kinases such as TAK1 or transautophosphorylation of T-loop serine residues (177 and 181 of IKKβ) for canonical
pathway activation.45 Dimerization of IKK/β monomers is known to play a role in the
activation or activity of the kinase. For example, dimerization mutations L654D/W655D
and W655D/L658D exhibit complete or partial loss of activation in a manner that correlates
with their degree of impairment in dimerization and failure to interact appropriately with
NEMO. Additionally overexpression of IKKβ has been shown to result in activation. More
recent studies suggest that IKKβ may exist as a dimer of dimers in cells and that
neighboring dimers may be able to autophosphorylate one another to drive activation46 or
an active kinase from a protomer in a neighboring dimer may activate an inactivate
protomer in a separate dimer without forming a true tetramer.47
In any event, it is widely accepted that the canonical NF-κB pathway is activated
by inflammatory cytokines, such as TNF, pathogen-associated molecules or antigen
receptors. For this pathway to function properly, IKKβ activation is both necessary and
sufficient and leads to the phosphorylation of IκB in a NEMO-dependent manner. The
non-canonical pathway is dependent on IKK and is activated by BAFF, lymphotoxin-B or
CD40 ligand, the upstream kinase NIK (NF-κB-inducing kinase) and phosphorylation of
p100.38 As this dissertation focuses on the activation of the NF-κB pathway by IKKβ in
response to the pro-inflammatory cytokine TNF, the non-canonical pathway will not be
discussed further.
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Once activated by phosphorylation of its T-loop serine residues, IKKβ exhibits high
activity and phosphorylates its substrate, IκB, and autophosphorylates several Cterminal serine residues. The autophosphorylation results in decreased IKKβ kinase
activity probably through another conformational change in the catalytic domain.48 The
phosphorylated C-terminal serine residues provide binding sites for phosphatases such
as PPM1A, PPM1B49 and PP2A50 that may dephosphorylate the T-loop serine residues.
Another mode of regulation is through the phosphorylation of serine 740 in the NBD, which
leads to the dissociation of the regulatory subunit NEMO. This also allows phosphatases
to dephosphorylate the T-loop serine residues.2
How else NEMO may regulate the activity of the IKK complex is under
investigation. Mutation of the MOD of NEMO may hamper activation of NF-κB.
Additionally, binding of NEMO to chains of polyubiquitin may also be key to activation of
the IKK complex and many groups have demonstrated NEMO binding to upstream
kinases with polyubiquitin chains, suggesting that NEMO may play a role in IKKβ activation
by directing the IKK complex to upstream kinases. NEMO may also activate IKKβ in
response to nuclear stimuli such as DNA damage. NEMO, free in the nucleus, may
become SUMOylated and may then be exported to the cytoplasm where it can activate
IKKβ and the NF-κB pathway. Furthermore, NEMO may also negatively regulate IKKβ
activity through interaction with phosphatases (PP2A and PP2C) and deubiquitinases
(CLYD and A20).1
Signaling upstream of the IKK complex
Signaling upstream of the IKK complex involves many adaptor proteins and likely
an upstream kinase (Figure 3). Following binding of TNF, the cytoplasmic tail of TNFR1
(TNF receptor 1) recruits a series of proximal adapter proteins through its death domain.
TRADD (TNFR-associated protein with a death domain) and RIP1 (receptor-interacting
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protein 1) bind to the death domain of TNFR1 through their own death domains though
the mechanism is poorly understood. TRADD also recruits FADD (Fas-associated protein
with death domain) again via their death domains and TRAF2/5 via a TRAF-binding
domain in TRADD. TRAF2/5 in turn recruits cIAP1 and 2 (cellular inhibitor of apoptosis 1
and 2), which facilitates the recruitment of the
ubiquitin chains required for the activation of the
IKK complex.45 TRAF2, along with the cIAPs,
mediates linear or K63-linked ubiquitination of
RIP1. RIP1 and TRAF2 thus cooperate to recruit
tumor growth factor β activated kinase (TAK1),
the upstream kinase likely responsible for
phosphorylation and activation of IKKβ and the
Figure 3: Signaling upstream of
the IKK complex. Signaling from
TNFR1 through proximal adaptor
proteins leads to activation of the
IKK complex through IKKβ T loop
phosphorylation (S177 and S181),
which is indispensable for canonical
NF-κB signaling. FADD, Fasassociated protein with death
domain; TRADD, TNFR-associated
protein with a death domain; TRAF,
TNFR-associated factor; cIAP,
cellular inhibitor of apoptosis; ubiq.,
ubiquitin. Image adapted from ref38

IKK complex.51 TAK1 is recruited to the adapter
proteins associated with TNFR1 via the TAK
binding proteins TAB2 and TAB3, which bind to
the K63 polyubiquitin chains on TRAF2, RIP1 or
NEMO. Furthermore, NEMO has been shown to
bind

K63

polyubiquitin

chains

on

RIP1

suggesting the ubiquitinated protein may bring
the IKK complex and the upstream kinase TAK1

together to promote IKKβ activation.41
TNF
TNF is synthesized as a 26 kDa, 233 amino acid propeptide that is cleaved by
TNF-converting enzyme into its 17 kDa, 157 amino acid form. TNF binds to TNFR1,
which is expressed on nearly all mammalian cells, as a homotrimer, resulting in the
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dissociation of the silencer of death domain (SODD) protein that represses TNFR1
signaling in the absence of TNF to activate the NF-κB pathway as previously described.
Activated macrophages are the primary source of TNF, though the propeptide can be
synthesized by other cells, including fibroblasts and tumor cells.52
Inactivation of NF-κB pathway signaling
Unfortunately, the mechanisms that regulate the termination of NF-κB signaling
are not yet well understood. It is known that IκB along with p105 and p100 are target
genes of NF-κB and serve as regulatory molecules that influence NF-κB activity. Newly
synthesized IκB, for example, can enter the nucleus and bind to NF-κB, causing it to
shuttle back to the cytoplasm. Post-translational modification of NF-κB is also implicated
in inactivation of pathway signaling. These post-translational modifications alter cofactor
binding or can result in the displacement or degradation of NF-κB to terminate signaling.51
Acetylation of p65, for example, results in decreased DNA-binding affinity.53 The ubiquitin
ligases SOCS-1 and PDLIM2 have been shown to drive proteasomal degradation of p65
bound to promoters.54-56
Phosphorylation of tumor suppressor proteins: NF-κB-independent IKK functions
Sequence analysis of IKKβ substrates using IκB peptides revealed a consensus
sequence in the C-terminus of p53. Phosphorylation of p53 typically leads to protein
stabilization by blocking Mdm2-mediated ubiquitination and degradation of the protein;
however, other phosphorylation events have been shown to lead to p53 degradation.
Studies with IKKβ and p53 showed that phosphorylation of p53 at S362 and S366 by IKKβ
resulted in β-TrCP-mediated ubiquitination and degradation of the protein. Furthermore,
activation of the NF-κB pathway by doxorubicin, which induces DNA damage, resulted in
IKKβ-induced p53 phosphorylation and degradation.57
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Tuberous sclerosis complex 1 and 2 are tumor suppressor proteins that form a
complex that controls the activity of molecular target of rapamycin (mTOR). TSC1 binds
to TSC2 and protects it from ubiquitination and degradation. TSC2 is a GTPase-activating
protein that converts RHEB-GTP to RHEB-GDP and its activity prevents the activation of
mTOR by RHEB-GTP. IKKβ has been shown to phosphorylate TSC1 at S487 and S511
following activation by TNF. This phosphorylation event results in the destruction of the
TSC complex and activation of mTOR, which provides a link between inflammation via the
NF-κB pathway and tumorigenesis via activation of the mTOR pathway.58
Phosphorylation of FOXO3a by IKKβ has also been found to lead to the protein’s
ubiquitination and degradation in the absence of Akt. Activated Akt has been shown to
phosphorylate FOXO3a, leading to the protein’s release from DNA and translocation to
the cytoplasm where the protein binds 14-3-3 and becomes sequestered. In the absence
of growth factor or survival stimuli, Akt is inactive and FOXO3a remains in the nucleus
where it controls the transcription of genes involved in control of cell cycle progression
and mitosis. However, in cells with inactive Akt, phosphorylation of FOXO3a by the IKK
complex and subsequent degradation of the protein has been shown. Importantly, this
regulation of FOXO3a by the IKK complex may contribute to tumor cell growth and
tumorigenesis.59
IKK knock-out models
IKK knock-out mice survive until a month past birth but have abnormal skin, lack
whiskers, and have limbs that do not form properly. These mice show reduced activation
of the NF-κB pathway in response to inflammatory signals but the remaining IKK complex
(composed of IKKβ homodimers and NEMO) is still capable of IκB phosphorylation and
pathway activation in response to TNF.60
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In mice, IKKβ deletion is embryonically lethal at day E13 due to massive apoptosis
in the liver and IKKβ knock-out mouse embryonic fibroblasts (MEFs) exhibit increased
apoptosis following treatment with TNF.61, 62 The knock-out mice can be rescued by
crossing IKKβ-/- mice with TNFR-/- mice but the resulting pups still only survive until one
month past birth. IKKβ knock-out MEFs still respond to certain stimuli associated with the
canonical IKKβ-IκB-NF-κB pathway but deletion of NEMO results in a complete loss of
this activity.1
Mouse embryonic fibroblasts lacking NEMO are unable to respond to TNF. Like
IKKβ-/- mice, mice lacking NEMO die during embryogenesis due to liver apoptosis and fail
to respond to pro-inflammatory, immune and pro-survival stimuli.63
IKK/β double knock-out mice die at E12 due to apoptosis and defective
neuralation. TNF, IL-1 and LPS are all unable to activate the NF-κB pathway in double
knock-out MEFs.64 Though crossing the double knock-out mice with TNF-/- mice does
extend survival and yields mice more closely resembling IKK-/- mice, these mice still die
during embryogenesis (day E16.5) due to neural tube defects.1
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Chapter 2: The NF-κB pathway and cancer
TNF and the tumor microenvironment
In 1863, Rudolf Virchow posed a link between inflammation and cancer and over
a century and a half later that link has been generally accepted.65 Furthermore, it is now
postulated that up to 20% of cancers are due to underlying inflammatory responses such
as infection, autoimmune disease or inflammation due to unknown causes. Many
correlations between inflammation and cancer exist, including: 1) the fact that patients
with inflammatory diseases are at increased risk for a diverse array of cancers including
cervical and ovarian cancers, 2) the risk of developing cancers such as breast or colon
cancer is decreased by the use of non-steroidal anti-inflammatory drugs, 3) inflammatory
pathways often operate downstream of oncogenic mutations, 4) inhibition of inflammatory
pathways, such as the NF-κB pathway, or inflammatory cells reduces the incidence of
cancer and 5) activation of inflammatory pathways or transfer of inflammatory cells
promotes tumor development. Two pathways of inflammation exist in cancer including the
extrinsic pathway, which is a pathway activated by inflammatory conditions that increase
the risk of cancer, and the intrinsic pathway, which is activated by genetic alternations that
activate inflammation. At least one of these pathways is active in most, if not all, tumors.66
This inflammation is caused by infiltrating immune cells, such as tumor-associated
macrophages, that secrete pro-inflammatory cytokines, including TNF into the tumor
microenvironment.67
The importance of TNF and the NF-κB pathway has been clearly established in
cancer. In resected tumor specimens, IKKβ is phosphorylated at S181 and thus activated
in approximately 50% of tumor specimens, including breast, oral, stomach, colon, liver,
and pancreatic tumor specimens. This phosphorylation is only seen in approximately 12%
of normal tissues, suggesting that IKKβ and the NF-κB pathway are inappropriately
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activated in cancer. Furthermore, in breast cancer tissues, there is a near perfect
correlation between the phosphorylation of IKKβ S181 and the presence of TNF and the
phosphorylation of IKKβ and the phosphorylation of IκB, suggesting that TNF in the
tumor microenvironment drives the chronic activation of the NF-κB pathway (Figure 1).58
Though REL deletions, mutations and amplifications have been seen in human cancers,
this continuous activation of IKKβ and the NF-κB pathway by TNF in the tumor
microenvironment likely plays a huge role in
solid tumor formation.35
Activation of the Ras-Raf signaling
pathway

results

in

the

production

of

chemokines and cytokines that promote
tumorigenesis via the intrinsic pathway.
Importantly, K-Ras is mutated in many
cancers, including those of the pancreas,
colon, small intestine and lung. However, the
extrinsic pathway likely also plays a role in
cancers such as pancreatic cancer where
both inflammation prior to a genetic lesion and
subsequent mutations in K-Ras drive cancer
progression.

The

intimate

relationship

Figure 1: Constitutive activation
of the NF-κB pathway in cancer
cells.
TNF
in
the
tumor
microenvironment drives activation
of
IKK
and
subsequent
phosphorylation and degradation of
IκB and translocation of NF-κB to
drive cancer cell survival and
chemoresistance.

between Ras activation and activation of IKK
and the NF-κB pathway will be discussed in detail in the next section.
The NF-κB pathway and solid tumors
Activation of the NF-κB pathway is implicated in a number of solid tumors, including
colon,58, 68-70 pancreatic,71-73 lung,74, 75 breast58, 76-79 and ovarian 80-82 cancers and has been
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shown to play a role in inflammation, transformation, proliferation, angiogenesis, invasion,
metastasis, chemoresistance and radioresistance.83 In this section, I will focus primarily
on cancers that were used as model systems in this dissertation.
Colon cancer
Though no colon cancer cell lines were used in the body of work presented in this
dissertation, the link between NF-κB activation and colon cancer is worth mentioning here.
Deletion of IKKβ in enterocytes is associated with a decreased incidence of colitisassociated tumor formation. In this model, mice were treated with dextran sulfate sodium
salt to mimic inflammatory bowel disease after an initial treatment with the procarcinogen
azoxymethan, which results in tumor formation in the distal colon. A 75% decrease in
tumor incidence was noted in the IKKβ knock-out mice compared to wild-type controls.
This decrease was due to increased apoptosis in knock-out mice. Furthermore, deletion
of IKKβ in myeloid cells decreased tumor incidence in the same model by 50% but this
was not related to apoptosis and was likely due to blocking the transcription of one or more
NF-κB-dependent genes.68 Additionally, phosphorylated IKKβ was detected in over 65%
of all colon cancer specimens analyzed by Mein Chi Hung’s group, suggesting there is a
connection between pro-inflammatory TNF in the tumor microenvironment and colon
cancer.58 Other groups have shown that NF-κB activation correlates with tumor
progression69 and inhibition of NF-κB with a superrepressor IκB (a nonphosphorylable
IκB with serine residues 32 and 36 converted to alanine residues) sensitizes colorectal
cancer cells to treatment with the chemotherapeutic CPT-11.70
Pancreatic cancer
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the US,
with a 5-year survival rate hovering around 5%.84 Three types of precancerous lesions
may form prior to the onset of pancreatic ductal adenocarcinoma. These lesions include
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intraductal papillary mucinous neoplasms (IPMNs), which form in the main pancreatic duct
or its branches, pancreatic intraepithelial neoplasias (PanINs), which form within
intralobular ducts and mucinous cystic neoplasms (MCN), which are epithelial neoplasms
that produce mucin. Each of these precancerous lesions are believed to represent the
progression from normal pancreatic cells to pancreatic ductal adenocarcinoma.85, 86 The
connection between mutant K-Ras and IKK activation has been well established in the
development of pancreatic cancer.
K-Ras is mutated in approximately 90% of pancreatic ductal adenocarcinomas and
this mutation can be seen in as many as 40% of PanIN lesions, suggesting the mutation
is a very early event.87, 88 Furthermore, nearly half of ductal lesions displaying no atypia
harbor the mutation and increased prevalence of this mutation is seen with increasing
atypia.85 In mice, K-Ras mutation appears to be a primary event that results in the
formation of premalignant ductal lesions that resemble human PanINs, but a second
mutation is required for malignant progression.89 NF-κB is constitutively activated in
approximately 67% of pancreatic adenocarcinomas90 and targeted inactivation of IKKβ in
KrasG12D mice has been shown to stall pre-malignant PanIN lesions from developing into
pancreatic ductal adenocarcinoma (PDAC).72,

73

The necessity of this constitutive

activation of NF-κB for development of PDAC was made clear by work showing that
pancreas-targeted IKKβ inactivation inhibited NF-κB activation and PDAC development in
KrasG12D and KrasG12D;Ink4a/ArfF/F mice.91 These mice develop PanIN lesions but do
not progress to PDAC when IKKβ is inactivated, supporting the importance of IKKβ
activation in pancreatic cancer and suggesting that inhibition of the kinase may serve to
prevent the development of the disease.72
The importance of IKK activation in K-RasG12V–driven pancreatic cancer has also
been established. Knocking K-RasG12V into the pancreatic acinar cells of mice results in
the development of PanINs and PDAC that perfectly resembles human disease.92
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However, if K-RasG12V is turned on in adult mice, the mice fail to develop PanINs and
PDAC in the absence of chronic pancreatitis, the onset of which induces PanINs and
PDAC. This work clearly demonstrates the necessity of inflammation for the formation of
K-Ras-driven PDAC.93
Lung cancer
Lung cancer is another devastating disease with a 5-year survival rate of
approximately 15%. To demonstrate the importance of IKKβ activation downstream of
oncogenic mutation in a mouse model of non-small cell lung cancer, the researchers in
Inder Verma’s group crossed IKKβfl/fl mice with KrasG12D mice to activate KrasG12D to initiate
tumor formation but inactivate IKKβ upon transduction by Cre lentiviral vectors. The
resulting KrasG12D/IKKβfl/fl mice survived longer (162 days median survival time compared
to 114 days) than KrasG12D mice when each were infected with an appropriate lentiviral
vector also encoding shRNA against p53 to speed tumor formation. Subsequent studies
determined that these results were due to a pro-proliferation contribution of the NF-κB
pathway in that particular model.94 Overexpression of IκB in lung cancer models has
been associated with increased sensitivity to paclitaxel, possibly through reduced VEGF
expression.75
Breast cancer
There is a near perfect correlation between the presence of TNF, activation of
IKKβ and phosphorylation of IκB in over one-third of breast cancer tissues. This
activation of IKKβ has been associated with phosphorylation of TSC1, which leads to
dissociation of the protein from TSC2 and the subsequent degradation of TSC2 and
activation of mTOR to drive VEGF production. Furthermore, this phosphorylation of TSC1
correlates with decreased survival of patients from whom the tissues were collected.58
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Estrogen receptor is expressed in approximately 70% of breast cancers and
mediates the activation of estrogen, which is a key player in the initiation and progression
of the disease. As the disease progresses, cancer cells lose their dependency for estrogen
and become estrogen receptor negative (ER-) and this loss of ER has been shown to
correlate with activation of the NF-κB pathway. Furthermore, ER is commonly used as a
predictor of response to endocrine therapy, such as tamoxifen, for the treatment of breast
cancer.76 DNA binding of NF-κB as measured by EMSA was much higher in ER- cell lines
such as MDA-MB-231 cells than in ER+ cells lines and when an ER+ cell line was
converted to an ER- cell line, NF-κB DNA binding activity doubled.77 Furthermore, the nonsteroidal anti-inflammatory agent sulindac has been shown to drive apoptosis in breast
cancer cells through inhibition of IKKβ. Importantly, MDA-MB-231 cells, which show high
activation of the kinase, were more sensitive to the drug than breast cancer cells with low
IKKβ activation.78 Additionally, transient transfection of an endocrine-resistant MCF-7 cell
line that has an approximately 50% higher level of NF-κB activity due to constitutive
activation of Akt with the nonphosphoryable IκB (S32A/S36A) restores NF-κB activity to
levels similar in control cells. Furthermore, tamoxifen treatment of cells transfected with
the nonphosphorylable IκB resulted in increased growth inhibition of the endocrineresistance cells compared to tamoxifen treatment alone. Additionally, treatment with the
IKKβ inhibitor parthenolide also enhanced tamoxifen-induced growth inhibition of the
resistant cells.95
Though NF-κB activation is more commonly associated with ER- breast cancers,
NF-κB activity has also been shown in a subset of ER+ breast cancers and is associated
with lower disease free survival. In these ER+ tumors, activation of NF-κB is shown to be
higher in tumors with lower ER (21-87 fmol/mg ER vs. ≥100 fmol/mg ER). 76
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The upregulation of NF-κB-related genes has also been implicated in inflammatory
breast cancer, which is a rare and aggressive form of breast cancer. These genes include
NF-κB genes such as NFKB1, RELA, NFKB2 and NEMO, tumor-promoting genes and
genes that regulate angiogenesis, proliferation, apoptosis and immune responses.96
Ovarian cancer
IKKβ has been identified as a major promoter of a TLR4-MyD88-NF-κB pathway
in epithelial ovarian cancer cells isolated from malignant ovarian cancer ascites and solid
tumors. MyD88 is an adapter protein for TLR4 and expression of the protein allows
signaling from TLR4 to NF-κB in MyD88+ epithelial ovarian cancer cells in response to
LPS. Pathway activation by LPS induced increased growth and cytokine production in
MyD88+ cells. Importantly, MyD88+ cells showed decreased sensitivity to the
chemotherapeutic paclitaxel compared to MyD88- cells. In patients treated with paclitaxel
and carboplatin following surgery, expression of MyD88 was correlated with decreased
time until recurrence (23 months compared to 42 months for patients not expressing
MyD88). Overall, these studies suggest that activation of the TLR4-MyD88-NF-κB
pathway allows the epithelial ovarian cancer cells to constitutively secrete proinflammatory cytokines to promote tumor progression and chemoresistance.80
Subsequent work by the same group showed that treatment with LPS or paclitaxel results
in increased NF-κB activity in MyD88+ cells but not MyD88- cells and that ectopic
expression of IKKβ in MyD88- cells could induce production of the same cytokines
produced by MyD88+ cells and restored TLR4 signaling. Furthermore, MyD88+ cells were
shown to be resistant to apoptosis following treatment with high levels of TNF while
MyD88- cells were sensitive to the treatment. Analysis of miRNAs in MyD88+ and MyD88cells identified hsa-miR-199a as being up-regulated in MyD88- cells compared to MyD88+
cells and a regulator of IKKβ in MyD88- cells, establishing a role for the IKKβ and the NFκB pathway in ovarian cancer.81 A particularly important implication for this work is the role
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it identifies for IKKβ and NF-κB in the development of resistance to paclitaxel. Though
nearly 90% of ovarian cancer patients respond to treatments such as carboplatin and
paclitaxel, most (again nearly 90%) will face recurrent disease.97 Pharmacological
inhibition of the NF-κB pathway has been shown to increase ovarian cancer cell sensitivity
to paclitaxel.82, 98 Furthermore, analysis of 42 primary tumors derived from patients with
follow-up data showed that patients with tumors expressing IKKβ in at least 25% of cells
had reduced overall survival (21 months compared to 29 months) compared to patients
with IKKβ expression in 25% or fewer of their tumor cells. Furthermore, pharmacological
inhibition or RNA interference of IKKβ resulted in decreased ovarian cancer cell viability.99
Cervical cancer
The role of NF-κB activation in cervical cancer is less clear than its role in
previously discussed cancers. Infection with human papillomavirus (HPV) from the high
risk subset of HPV is a major risk factor for the development of cervical cancer. The E6
and E7 genes carried by HPV-16, a prototypical high-risk HPV strain, are required to
immortalize human epithelial cells.100 E6 expression results in p53 degradation101 and
immortalization through activation of hTERT102 while the E7 protein functions to inactivate
retinoblastoma and thereby promotes progression of the cell cycle.103 These proteins also
regulate NF-κB and NF-κB activation has been shown to decrease following
immortalization of the epithelial cells more frequently giving rise to cervical cancer.104 The
mechanism by which HPV inactivates NF-κB signaling appears to be through inhibition of
the IKK complex.105 In the context of HPV infection and HPV-immortalization of cells, it
appears that NF-κB actually plays a role in controlling the proliferation of virally infected
cells and inhibition of NF-κB using the IκB superrepessor resulted in increased
proliferation and colony formation of immortalized cells. Subsequent studies revealed that
p65 functions to decrease expression of a short sequence of DNA upstream of HPV-16
E6 and thereby inhibits proliferation.106
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However, as cervical cancer progresses, the role of NF-κB seems to shift from
inhibitory to activating. For example, NF-κB overexpression has been shown to increase
HeLa and C33A cell viability while knockdown of NF-κB suppresses cell viability.
Furthermore, overexpression of NF-κB results in increased colony formation by both cell
lines, indicating that NF-κB promotes cervical cancer cell viability and growth. In these
studies it was found that NF-κB overexpression also increased miR-130a levels while
knockdown of the protein decreased miR-130a levels. Expression of this microRNA is key
for regulating TNF mRNA levels and the NF-κB/miR-130a/TNF feedback loop may be
responsible for maintaining a level of TNF that promotes tumor growth and prevents
apoptosis of cancer cells.107
This seemingly two-faced role of NF-κB during the progression of cervical cancer
is supported by immunohistochemical analysis of human tissues. In a series of 106
cervical intraepithelial neoplasia (CIN lesions) and cervical cancer lesions analyzed, the
NF-κB pathway was activated during the course of disease progression. In the normal
cervix and early lesions (CIN1 lesions), p65 was localized exclusively to the cytoplasm but
increased nuclear localization of p65 was seen during the progression of disease through
CIN2 and CIN3 stages and the development of squamous-cell carcinoma of the cervix. As
NF-κB serves to repress HPV transcription,108 the downregulation of NF-κB is likely
required for initial infection and immortalization of cells but becomes less important during
progression of the disease. Furthermore, NF-κB’s role in a myriad of tumor-promoting
activities may select for its increased expression in precancerous lesions as the disease
progresses, though the nuclear expression of NF-κB did not correlate with survival of
patients, aggressiveness of disease or clearance or persistence of HPV infection.109
Nevertheless, inhibition of the NF-κB pathway with curcumin and aspirin has been shown
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to sensitize cervical cancer cells to chemotherapeutic agents such as cisplatin,110 which
is consistent with the pathway’s role in the development of chemoresistance.
Overall, the studies presented in this chapter establish TNF, IKKβ and NF-κB as
key mediators of tumorigenesis and demonstrate the pathway’s importance in the
progression of many solid tumors types. The next chapter will focus on the considerable
efforts that have been made to develop IKKβ inhibitors and the challenges associated with
such a task.
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Chapter 3: Targeting IKKβ
Rationale for targeting IKKβ
Nearly one-third of all cancers display an oncogenic mutation in Ras111 and IKKβ
has been shown to be activated in 50% of tumors58 and its activation may serve as a
second hit that results in the development of cancer.68, 72, 94 The case for pancreatic cancer,
for example, is quite compelling. As mentioned previously, as many as 95% of human
pancreatic carcinomas have been shown to harbor a mutation in codon 12 of the KRAS
gene87 and NF-κB is constitutively activated in approximately 67% of pancreatic
adenocarinomas90 and correlates with lower overall survival of patients.112 Constitutive
activation of NF-κB has great implications for cancer research as it may lead to the
transcription of anti-apoptotic genes, among others, and chemoresistance.113 Importantly,
knock-out of IKKβ stalls Kras-driven pancreatic cancer at PanIN lesions, demonstrating a
mechanistic link between mutated Kras and IKKβ in the initiation of PDAC, suggesting
IKKβ is an attractive target for anticancer therapy.72 Furthermore, research suggests that
inhibition of IKKβ may increase the efficacy of many chemotherapeutics such as
gemcitabine,114, 115 paclitaxel82, 98 and cisplatin.110
Current IKKβ inhibitors
By the mid-2000’s research uncovering the undeniable role of the NF-κB pathway
in inflammation and cancer had launched the development of many novel IKKβ inhibitors
and the identification of natural products that blocked the kinase’s actions. The beststudied of these inhibitors include BAY 11-7085,116 ML120B,117 TPCA-1,118 BMS345541119
and Bayer ‘compound A’120 and the natural products curcumin121 and parthenolide.122
Despite promising results in pre-clinical models, none of these drugs have been clinically
approved for the treatment of cancer, due to unexpected toxicities arising from targeting
IKKβ or poor bioavailability. For example, pre-treatment of HeLa cells with ML120B for 1
hour followed by stimulation with TNF (30 ng/mL) for 5 minutes to drive activation of IKKβ
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and phosphorylation of IκB, results in marked reduction in IκB phosphorylation.
Unfortunately, when mice were dosed with ML120B for 7 days, a decrease in peripheral
blood T cell and B cell numbers and an increase in granulocyte neutrophils was observed
and mice had to be removed from the treatment due to toxicity issues.117,

123

These

toxicities likely arise from inhibiting signaling through IKKβ required for proper immune
functioning. The natural product parthenolide, on the other hand, did not display notable
toxicity in a Phase I trial but instead suffered from the fact that a botanical product
containing the natural product was not able to produce detectable levels of parthenolide
in plasma.124 Taken together, these data suggest IKKβ represents a potential anticancer
target, but its global inhibition is detrimental and careful design will be required to develop
an IKKβ inhibitor that is viable for human use.
Recent crystal structures of IKKβ
Recent crystal structures of IKKβ have provided structural insight that is quite
valuable for the rational design of IKKβ inhibitors. One, published in 2011, was of Xenopus
laevis IKKβ and yielded a proper understanding of the domain architecture of IKKβ.46 In
this structure, the kinase domain of IKKβ is at the N-terminus of the protein and an
ubiquitin-like domain follows. A scaffold/dimerization domain that contains previously
predicted leucine zipper (LZ) and helix-loop-helix (HLH) domains is then followed by the
C-terminal NEMO binding domain (Figure 1A). Previous models for the activation and
subsequent deactivation of IKKβ depended on interactions facilitated by the predicted, but
non-existent, LZ and HLH domains.125 Furthermore, hydrophobic residues of the predicted
LZ domain actually point inward in the crystal structure and, therefore, are unavailable for
mediating dimerization as the previous models proposed. Additionally, the previously
discussed MEK consensus sequence motif of SxxxS (S represents S177 and S181 for
IKKβ) was found in the activation loop of IKKβ. The crystal structure of Xenopus laevis
IKKβ (which is commonly referred to as xIKKβ) was obtained using an IKKβ of residues
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4–675 with S177 and S181 mutated to glutamic acid in complex with inhibitor. The crystal

Figure 1: Crystal structure of Xenopus laevis IKKβ. A) Domain architecture of IKKβ
showing the KD, ULD, SDD and NBD of IKKβ B) Crystal structure of Xenopus laevis
IKKβ with the KD, ULD, SDD and N- and C-termini of the kinase labeled C) Tetramer
(dimer of dimers) formed by xIKKβ D) Close-up view of the activation loops of
neighboring protomers. This research was originally published by Nature Publishing
Group. Xu, G. et al. Crystal structure of inhibitor of kappaB kinase beta. 2011. Nature.
2011; 472: 325-330.46
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structure captures IKKβ in a dimer resembling a pair of scissors with each kinase domain
and ubiquitin-like domain representing handles and the scaffold/dimerization domain
representing the blades of the shears, though the domains still intimately associate with
one another (Figure 1B). The kinase domain exhibits a bilobal kinase fold, which is typical
of all kinases, and the ubiquitin-like domain indeed has an ubiquitin fold and the
hydrophobic surface patch of ubiquitin that is recognized by ubiquitin-binding proteins. The
inhibitor binds to the hinge loop that connects the N- and C-lobes of the kinase domain of
IKKβ, which is the same site where the adenine of ATP would bind and is the site targeted
by most IKKβ inhibitors. Not surprisingly, the kinase domain is in a conformation that is
not compatible with that of an active kinase. For example, the C-terminal anchor of the
activation segment is in a conformation that results in loss of essential interactions with
the catalytic center. Pulldowns with the C-terminal region of IκB and full-length IKKβ or
the ULD-SDD region of IKKβ showed that the ankyrin repeats and PEST region of IκB
interact with ULD-SDD IKKβ. Further studies demonstrated that the interaction directs the
specificity of IKKβ to S32 and S36 of IκBa and away from its PEST sequence. Additionally,
the interaction between the ubiquitin-like domain and the KD was found to allosterically
position the KD in a confirmation that is favorable for catalysis. Lastly, the SDD domain
was found to mediate dimerization between the two IKKβ monomers in the dimer. The
interactions key for dimerization were mainly hydrophobic interactions between residues
localized towards the end of the bundle. The tetrameric nature of the IKKβ crystal structure
derived in these studies suggests that IKKβ may form a dimer of dimers that allows one
protomer to activate the neighboring dimer through autophosphorylation (Figure 1C and
D).46
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A more recent crystal structure of human IKKβ residues 1-664 in complex with the
staurosporine analog K252a captured an asymmetric dimer of IKKβ in which one IKKβ

Figure 2: Crystal structure of an asymmetric dimer of human IKKβ. A) Ribbon
diagram of the asymmetric human IKKβ dimer and B) overlay of the
unphosphorylated and phosphorylated human IKKβ protomers. C) Overlay of the
KDs of unphosphorylated and phosphorylated human IKKβ bound to inhibitor. D)
Comparison of the pSer interactions of pS181 of human IKKβ and activated PKA.
The PKA activation loop is shown in gray while that of IKKβ in shown in red. A bound
peptide substrate is shown in blue. This research was originally published in J. Biol.
Chem. Liu, S. et al. Crystal structure of a human IkappaB kinase beta asymmetric
dimer. J. Biol. Chem. 2013; 288: 22758-67.47
was phosphorylated at S177 and S181 while the other IKKβ protomer was not, yielding
insight into the structural changes IKKβ undergoes when activated.47 The most significant
differences between phosphorylated and nonphosphorylated IKKβ occurred in the Nterminal lobe and at the activation loop (Figure 2A). Furthermore, the SDD of the
unphosphorylated protomer (which is in gray) is rotated 6° away from the KD compared
to the orientation of the SDD of the phosphorylated protomer and its KD (Figure 2B).47
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The activation loop of the phosphorylated IKKβ (residues 166–194) assumes a
conformation characteristic of an active kinase, as expected. The corresponding region of
the unphosphorylated IKKβ is not well defined and is in a conformation that is not
compatible with protein substrate binding (Figure 2C). As K252a binding is identical in
both the phosphorylated and nonphosphorylated IKKβ protomers and packing of the two
IKKβ protomers was equal, the differences in the flexibility and conformation of the two
protomers is likely due to the differential phosphorylation. The three phosphate oxygens
of pS181 interacted directly through ionic interactions with the cationic cluster formed by
R144 from the catalytic loop and K171 from the activation loop. Furthermore, one of the
phosphate oxygens formed hydrogen bonds to the main chain amide nitrogens of pS181
and T180 (Figure 2C). These interactions likely provide a link to the catalytic center and
stabilize the correct orientation of the catalytic base D145 and allow for the formation of
the polypeptide substrate pocket. This is similar to what is seen with other kinases, such
as Protein Kinase A (PKA) (Figure 2D).47
These distinct conformations of the active and inactive IKKβ protomers reveals a
well-formed peptide-binding pocket in active, but not inactive IKKβ (Figure 3A and B).
Differences in the conformations of these crystal structures may allow targeting of active
but not inactive IKKβ.47
Unlike xIKKβ, the human IKKβ dimer adopted an open conformation with its KDs
well separated, which is in contrast to the closed conformation adopted by xIKKβ (Figure
4A and B). Furthermore, human IKKβ did not form a dimer of dimers but rather formed
contacts with a crystal symmetry-related dimer at the KD and the N-terminal ends of the
SDD to form a face-to-face KD-KD dimer. The activation loop (shown in red) in the
nonphosphorylated human IKKβ molecule is close to the active site of the activated KD
(Figure 5B), which is in contrast to what is seen with the dimer of dimers of xIKKβ (Figure
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5A). This orientation may facilitate the trans-phosphorylation of an unactivated KD by an
active kinase domain.47

Figure 3: Comparison of the substrate binding sites in unphosphorylated and
phosphorylated human IKKβ. The substrate binding site is not formed in the
unphosphorylated protomer (A) but is well-formed in the phosphorylated protomer
(B), allowing the binding of a peptide substrate. K252a is shown as a stick model and
the substrate peptide is shown in blue. This research was originally published in J.
Biol. Chem. Liu, S. et al. Crystal structure of a human IkappaB kinase beta
asymmetric dimer. J. Biol. Chem. 2013; 288: 22758-67.47
Historic IKKβ Inhibitors
Historically, IKKβ inhibitors developed by pharmaceutical companies target the
ATP binding site and thus the resting state of IKKβ. This mode of inhibition prevents the
activation of IKKβ and likely results in the previously described toxicities. The crystal
structure of the asymmetric IKKβ dimer sheds light on the possibility that the active, posttranslationally modified form of IKKβ represents a unique form of the kinase that can be
targeted. This is particularly valuable information when coupled with the finding that IKKβ
is chronically activated by TNF in the tumor microenvironment,58 which should result in
a pool of phosphorylated IKKβ in cancerous cells (Figure 6). We hypothesized that small
molecules targeting the phosphorylated form of IKKβ that accumulates in cancer but not
the resting, unphosphorylated form of IKKβ that is found in normal tissues could serve as
non-toxic inhibitors of IKKβ and the NF-κB pathway. As such, my dissertation work has
focused on characterizing two small molecule inhibitors of IKKβ that we believe may target
the activated form of the kinase to inhibit tumor growth without inducing toxicities.
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Figure 4: Comparison of the open human IKKβ dimer (top) and
the xIKKβ closed dimer (bottom). A) Human IKKβ forms a faceto-face KD dimer with another dimer while B) xIKKβ forms a closed
dimer of dimers. This research was originally published in J. Biol.
Chem. Liu, S. et al. Crystal structure of a human IkappaB kinase
beta asymmetric dimer. J. Biol. Chem. 2013; 288: 22758-67.47
Identification of novel IKKβ inhibitors 13-197 and 25-4
IKKβ activated by phosphorylation of its two T loop serine residues is found in
nearly 50% of surgical tumor specimens but in only approximately 10% of normal tissues.
Furthermore, there is a perfect correlation between the presence of the pro-inflammatory
cytokine TNF and phosphorylation of IKKβ, in addition to a perfect correlation between
phosphorylation of IKKβ and phosphorylation of its substrate, IκB, in these tissues.58 This
suggests IKKβ is constitutively activated in tumor specimens in response to TNF in the
tumor microenvironment, which consequently leads to the constitutive activation of NFκB.
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As such, we sought to develop inhibitors of the NF-κB pathway. We took two routes
to accomplish this task. First, we
screened a library of novel small
molecules for activity against TNFinduced

IKKβ-mediated

NF-κB-

driven transcription and identified
the quinoxaline urea analog 13-197
as an inhibitor of the NF-κB pathway
(Figure 7A).126-128 The quinoxaline
core of 13-197 is considered a
privileged scaffold as it is found in a
number of natural products and
commercially available drugs such
as the smoking cessation drug
Varenicline.129 A follow-up kinase
screen

and

mechanism-based

studies

revealed

that

13-197

inhibits NF-κB-driven transcription
by targeting the kinase IKKβ. As
information

regarding

the

prevalence of TNF in the tumor
microenvironment and consequent

Figure 5: Comparison of the Xenopus laevis
and human IKKβ dimers. A) The activation
loop of xIKKβ (which is shown in red) is far from
the activation loop of the neighboring protomer.
B) The KD of the nonphosphorylated human
IKKβ molecule is close to the active site of the
activated KD. This orientation may facilitate the
trans-phosphorylation of an unactivated KD by
an active kinase domain. This research was
originally published in J. Biol. Chem. Liu, S. et
al. Crystal structure of a human IkappaB kinase
beta asymmetric dimer. J. Biol. Chem. 2013;
288: 22758-67.47

activation of the NF-κB pathway has implicated over-activation of IKKβ, and not just
mutation of IκB or amplification or rearrangement of NF-κB subunits, in the constitutive
activation of the NF-κB pathway, we tested this small molecule for anticancer activity in
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cell lines and an orthotopic mouse model of pancreatic cancer and saw the small molecule
was active without inducing toxicities associated with known IKKβ inhibitors.
The small molecule is a non-ATP competitive inhibitor of IKKβ and initial studies
suggest 13-197 probably best occupies a pocket that is formed following the activation of
resting IKKβ. Upon phosphorylation of S177 and S181 of IKKβ and activation of the
kinase, the kinase undergoes a conformational change that creates potential binding sites
that can be targeted by small molecules. Small molecules targeting these sites are likely
to target the activated but not inactive form of the kinase.47 We believe 13-197 exhibits
anticancer activity without inducing toxicity by inhibiting an activated form of IKKβ while
allowing the transient activation of the protein. We hypothesize that constitutive activation
of the NF-κB pathway by TNF results in the sustained activation of the IKK complex in
many solid tumors (See Figure 6 for model). We believe this sustained stimulation of IKKβ
results in the accumulation of phosphorylated IKKβ that can be targeted by
pharmacological inhibitors to allow successful targeting of the kinase for anticancer
therapy. In our model, TNF in the tumor microenvironment drives the chronic activation
of IKKβ by phosphorylation of the kinase’s T loop serine residues (S177 and 181). Once
phosphorylated on the T loop serine residues, IKKβ exhibits high activity and
autophosphorylates a stretch of serine residues on its C-terminus, which provides docking
sites for phosphatases that dephosphorylate the T loop serine residues to inactivate the
kinase. Phosphorylation of the T loop serine residues of IKKβ is detectable minutes
following stimulation with TNF,125 making the transient activation of IKKβ very rapid.
Furthermore, as phosphorylation of the C-terminal serine residues is an intramolecular
event, this process should also occur quickly. However, the dephosphorylation of the
kinase by phosphatases is a bimolecular event and is thus the rate-limiting step in the
deactivation of IKKβ. Therefore, we propose that a hyperphosphorylated form of IKKβ in
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which the T loop serine residues and C-terminal serine residues are phosphorylated
accumulates in cancer. We hypothesize that this form of IKKβ is an ideal target for
anticancer therapy and targeting this form will allow the transient activation of IKKβ that is

Figure 6: Model for this progressive phosphorylation of IKKβ and its
accumulation in cancer tissues. TNF in the tumor microenvironment drives the
chronic activation of IKKβ by phosphorylation of the kinase’s T loop serine residues.
Once phosphorylated on the T loop serine residues, IKKβ exhibits high activity and
phosphorylates a stretch of C-terminal serine residues, which provides docking sites
for phosphatases that dephosphorylate the T loop serine residues to inactivate the
kinase. Phosphorylation of the T loop serine residues of IKKβ is very rapid.
Furthermore, as phosphorylation of the C-terminal serine residues is an
intramolecular event, this process also occurs quickly. However, the
dephosphorylation of the kinase by phosphatases is a bimolecular event and is thus
the rate-limiting step in the deactivation of IKKβ.
required for normal immune functioning but will block the chronic activation of IKKβ that
drives tumorigenesis. As such, we tested small molecule 13-197 for activity against
activated IKKβ and preliminary experiments indicate the small molecule indeed targets
activated IKKβ.
In our second approach to designing an inhibitor of the NF-κB pathway, we hoped
to target IKKβ by designing a small molecule inhibitor that featured the -methylene-butyrolactone of the known IKKβ and NF-κB subunit p65 inhibitor parthenolide.122, 130 After
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screening a small library of -methylene--butyrolactones against TNF-induced IKKβmediated NF-κB-driven transcription, we identified the small molecule 25-4 (Figure 7B) as
an inhibitor of NF-κB-driven transcription.131 This small molecule likely targets surfaceexposed C179 of IKKβ and a surface-exposed cysteine residue in NF-κB, likely C38.
C179, found in the activation loop of IKKβ, is primed for targeting as it sits between serine
residues 177 and 181, which are phosphorylated to drive the activation of IKKβ.125, 132
Cysteine residue 38 in NF-κB plays an important role in the protein’s activation of gene
expression.133
As briefly mentioned, parthenolide, a sesquiterpene lactone natural product, also
targets IKKβ and NF-κB subunit p65 through covalent interaction with the sulfhydryl group
of C179 of IKKβ and C38 of NF-κB.122, 130, 134, 135 The sulfhydryl groups on C179 of IKKβ
and C38 of NF-κB covalently react with the Michael acceptor in the -methylene-butyrolactone moiety of parthenolide, which results in the inhibition of the NF-κB
pathway.122 Parthenolide has displayed anticancer effects in cervical, breast, lung and
pancreatic cancers and potentiates the effects of clinically approved chemotherapeutics
such as gemcitabine, paclitaxel and cisplatin.136-138 Despite these remarkable activities,
Parthenolide suffers from poor water solubility, is unstable under acidic and basic
conditions and affords few opportunities for optimization due to structural complexity.139,
140

Parthenolide’s core structure features a highly functionalized, fused cyclodecane

lactone that is decorated by an epoxide, an E-alkene and four stereocenters and is trans
fused to an -methylene--butyrolactone.134 Recently, the first total synthesis of
Parthenolide was reported.141 This complicated structure limits our ability to easily
generate the analogs that would allow us to perform the extensive structure activity
relationship (SAR) studies required to identify compounds with improved biological activity
and drug-like properties.
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Our main goal in our project with 25-4, which inhibits the NF-κB pathway by
covalently binding to IKKβ and NF-κB, was to identify a highly modifiable core that, like
parthenolide, contains the -methylene--butyrolactone moiety and is expected to target
proteins through covalent interactions via its Michael acceptor. In our preliminary studies,
25-4 has been shown to inhibit phosphorylation of the IKKβ substrate IκB, reduce cancer
cell viability and induce caspase 3/7 activation and PARP cleavage in cancer cell lines.
Furthermore, it has reduced tumor growth in an orthotopic model of ovarian cancer. Very
importantly, the small molecule did not exhibit overt toxicity at therapeutic doses in mice
and its structure affords us an opportunity to make structural changes that will allow us to
conduct SAR studies that will potentially identify more potent and more specific inhibitors
of the NF-κB pathway. As such, this project has identified a core that may be suitable for
use as an IKKβ and/or p65 inhibitor and future studies will be aimed at improving the druglike properties and specificity of the small molecule and identifying the form of IKKβ
targeted by this non-toxic IKKβ inhibitor.
Treatment of cancer cells with small molecules 13-197 and 25-4 resulted in
impaired IκB phosphorylation, decreased cancer cell viability and increased apoptosis in
cancer cell lines and decreased tumor growth and metastasis in orthotopic mouse models
of cancer without inducing the toxicities associated with commercially available IKKβ
inhibitors. We hypothesize their lack of toxicity is due to selective inhibition of
phosphorylated IKKβ. Their selective inhibition of phosphorylated IKKβ allows the
transient activation of IKKβ prior to inhibition. Allowing this transient activation of IKKβ
appears to diminish toxicity in normal tissues while inhibition of sustained IKKβ activation
appears sufficient for induction of cancer cell death, making phosphorylated IKKβ an
attractive target for cancer drug discovery. The studies presented in this dissertation have
been aimed at establishing 13-197 and 25-4 as small molecule inhibitors of IKKβ and have
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identified functional groups key for their activity. Future studies will be aimed at
determining if and how the small molecules selectively target phosphorylated forms of
IKKβ and exploring the off-target effects of these small molecules.

Figure 7: Small molecules 13-197 and 25-4. A) The quinoxaline urea 13-197 and
B) the spirocylic -methylene--butyrolactone 25-4. Small molecule 13-197 was
developed by Drs. Qianyi Chen, Rajkumar Rajule, Sandeep Rana and Yogesh
Sonawayne.126-128 25-4 was developed by Dr. Sandeep Rana. 131
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Chapter 4: Materials and General Methods
Chemicals and reagents
The quinoxaline urea analog 13-197 was synthesized and purified (>98%) as previously
described.126, 127
The -methylene--butyrolactone 25-4 and its analogs were synthesized and purified as
previously described.131 HPLC-grade methanol was obtained from Fisher Scientific (Fair
Lawn, NJ, USA). Triethanolamine (≥99.5%) was obtained from Sigma Life Science (St.
Louis, MO, USA). Tris(2-carboxethyl)phosphine hydrochloride (98%) was obtained from
Alfa Aesar (Ward Hill, MA, USA). 5-TAMRA azide was obtained from Lumiprobe
(Hallandale Beach, Florida, USA). TAMRA-Azide-biotin was obtained from Click
Chemistry Tools (Scottsdale, AZ, USA). CuSO4·5H2O (≥98%) VWR International (West
Chester,

PA, USA. Tris[(1-benzyl-1-H-1,2,3-triazol-4-yl)methyl]-amine (97%) was

obtained from Aldrich (St. Louis, MO, USA).
Cell lines and culture conditions
Human pancreatic cancer cell lines MIAPaCa-2, PANC-1, Capan-2 and SUIT-2, cervical
cancer cell line HeLa and breast cancer cell line MDA-MB-231 were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) high glucose supplemented with 10% fetal bovine
serum (FBS). Human embryonic kidney cells (HEK cells) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) low glucose supplemented with 10% fetal FBS. Human
ovarian cancer cell line A2780 and pancreatic cancer cell lines Capan-2 and Hs766T were
cultured in Roswell Park Memorial Institute-1640 medium (RPMI) supplemented with 10%
FBS. Human lung cancer cell line luciferase A549 (generous gift from Prof. Brasier,
University of Texas Medical Branch, Galveston, TX) was cultured in DMEM high
supplemented with 10% FBS and 100 µg/mL hygromycin B. IKK knock-out (-/-) and IKKβ
knock-out (-/-) mouse embryonic fibroblast (MEF) cells (generous gift from Prof. I. Verma,
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Salk Institute) were grown in DMEM high medium with 10% FBS and 1% PencillinStreptomycin as were wild-type MEFs.
Cell lysis
Cytoplasmic fractions were generated by harvesting cells on ice in Buffer A (10 mmol/L
HEPES, 10 mmol/L KCl, 0.1 mmol/L EDTA, and 2 mmol/L DTT) containing protease and
phosphatase inhibitors. The cells were allowed to swell on ice for 30 min and 1.25% NP40 was added and the samples were centrifuged in the cold. The resulting supernatant
was transferred to a new tube and designated as the cytoplasmic fraction. To obtain
nuclear fractions, Buffer C (20 mM HEPES, 420 mM NaCl, 5 mM EDTA, 5 mM DTT, 10%
glycerol) containing protease and phosphatase inhibitors was added the remaining pellet.
The samples were incubated on ice with intermittent agitation over a period of 30 min and
were then centrifuged in the cold. The resulting supernatant was designated the nuclear
fraction. All samples were stored at -80°C until needed.
Whole cell lysates were generated by harvesting cells on ice in HNTG lysis buffer (20 mM
HEPES, pH 7.5, 25 mM NaCl, 0.1% Triton X-100, 10% glycerol) containing protease and
phosphatase inhibitors. The cells were allowed to swell on ice for 30 min and the samples
were centrifuged in the cold. The resulting supernatant was transferred to a new tube and
designated as a whole cell lysate. All samples were stored at -80°C until needed.
For click chemistry, cells were harvested via scraping in 1X PBS with protease and
phosphatase inhibitors and sonicated for 15 min. Lysates were spun and the soluble
fraction (supernatant) was collected and transferred to a new tube. All samples were
stored at -80°C until needed.
Western blotting
Cytoplasmic fractions or whole cell lysates were prepared from control and treated cells
as described above. The cell lysates (25 µg) were resolved in 4% to 20% denaturing
polyacrylamide gel (Bio-Rad) and transferred to polyvinylidene difluoride (PVDF)
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membranes (Millipore). The membranes were incubated with the following antibodies:
rabbit anti-p-IKK/β (Cell Signaling 2697), rabbit anti-IKKβ (abcam EPR6043), rabbit antiIκB (Cell Signaling 4812), mouse antiphospho-IκB (Cell Signaling 9246) or mouse antiPARP (Cell Signaling 9542). Internal loading control for cytoplasmic fractions and whole
cell lysates used mouse anti-tubulin (Cell Signaling 3873) or GAPDH (Santa Cruz
Biotechnology, Inc. sc-25778). These primary antibodies were incubated with horseradish
peroxidase–conjugated specific secondary antibodies. The signals were developed by
using Amersham ECL Prime Western Blotting Detection Reagent (General Electric
Healthcare Life Sciences).
Data processing and statistical analysis
P-values were determined using one way ANOVA in SigmaPlot and values < 0.05 were
considered significant.
IC50 values were derived from plotting cell viability against drug concentration and curvefitting the data using a four-parameter logistic curve in SigmaPlot.
κB-luciferase assay
A549 luciferase cells were seeded in white 96-well plates at a density of 50,000 cells per
well and incubated overnight. Cells were then treated with the indicated concentrations of
drugs for 2 hours. Cells were then stimulated with 20 ng/mL TNF (Panomics) for 3 hours.
AlamarBlue (abSerotec) was added (which served as a control for seeding and viability)
and the cells were incubated for 3 additional hours. ONE-Glo Luciferase reagent
(Promega) was added to each well and cells were incubated at room temperature for an
additional 10 min before luminescence was measured at 1000 ms integration on a
SpectraMax M5e plate reader.
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Click chemistry
For click chemistry with purified proteins, purified IKKβ or p65 (250 ng in a total volume of
200 µL) was incubated with 10 µM 31-036 for 1 hour. 5-TAMRA azide (Lumiprobe) (0.1
mM from a 1 mM DMSO stock) and click chemistry reagents (1 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP) from 50 mM stock in water, 1 mM CuSO4·5H2O from a
freshly prepared 50 mM stock in water, and 0.1 mM tris[(1-benzyl-1-H-1,2,3-triazol-4yl)methyl]-amine (TBTA) from 10 mM stock in DMSO) at a total volume of 48 µL were
added for 1 hour and then the reaction was quenched with ice cold methanol and stored
at -20°C to precipitate. The resulting precipitate was spun and the methanol was removed.
The pellet was resuspended in 4% SDS buffer (4%SDS, 150 mM NaCl, 50 mM TEA pH
7.4) and 2X sample buffer (20% glycerol, 0.2% bromophenol blue, 1.4% β
mercaptoethanol) to 1X. Samples were resolved on 4% to 20% denaturing polyacrylamide
gel (Bio-Rad) and visualized using the Typhoon 9410 Variable Mode Imager.
For click chemistry in cells, cells were treated with the indicated concentration of 31-036
for 1 h and then cells were harvested as described above. 200 µg of total protein in 152
µL total volume was incubated with 48 µL of the same click chemistry cocktail described
above to give 200 µL total volume. Click chemistry was continued as described above.
Cellular viability assay
Cellular viability was determined by alamarBlue Cell Viability Assay (Life Technologies) or
PrestoBlue Cell Viability Assay (Life Technologies) according to manufacturer’s
instructions. MIAPaCa-2, A2780, MDA-MB-231, Hs766T, AsPC-1, luciferase A549, SUIT2 and PANC-1 cells were incubated with compound in at least duplicate in a 96-well plate
and then incubated for 24, 48 or 72 hours at 37°C. AlamarBlue solution was added to each
well (equal to 10% volume of the medium in the well) and incubated for 3 hours at 37°C
or PrestoBlue solution was added to each well (equal to 10% volume of the medium in the
well) and incubated for 30 minutes at 37°C. The fluorescence of the solution was
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measured at 560 nm excitation and 590 nm emission using SpectraMax M5e fluorescence
plate reader. Dose–response curves were evaluated using the National Cancer Institute
(NCI) algorithm: Tz = number of control cells at time t0, C = number of control cells at time
t, and T = number of treated cells at time t; 100 × [(T - Tz)/(C - Tz)].
PARP cleavage
Cells were treated as indicated and harvested by collecting media, trypsinizing cells, and
centrifuging to obtain a combined cell pellet from all steps. Cells were lysed in radio
immuno precipitation assay (RIPA) buffer (150 mM NaCl, 1.0% Triton X-100, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate, 50 mM Tris, pH 8.0) and protein content was
resolved on 4% to 20% denaturing polyacrylamide gel (Bio-Rad). PARP cleavage was
determined via Western blotting using anti-PARP antibody.
Caspase 3/7 assay
3,000 SKOV3 cells/well were plated in a white, clear bottom, sterile 96 well dish in 95 µL
and incubated overnight. The next day, cells were treated with 5 µL compounds to yield
the final drug concentration indicated. Cells were incubated with compound for 24 h.
AlamarBlue was added to each well and cells were incubated for another 3 hours.
Fluorescence (560ex/590em) was measured on the SpectraMax M5 e plate reader. 110 µL
Caspase Glo-3/7 reagent was added to each well and mixed by the plate reader at 300500 rpm for 30 seconds. The plate was incubated at room temperature for 1 h.
Luminescence was measured on the SpectraMax M5 e plate reader.
Colony formation assay
HeLa cells were plated in 6-well plates at a density of 500-1000 cells per well and cultured
for 24 h, followed by drug treatment for 48 h at 37°C. DMSO was used as a control. Then,
the supernatant fluid was replaced with fresh medium and the cells were cultured for 7 d.
Cells were washed twice with PBS and then fixed with methanol for 15 m, followed by
0.1% crystal violet staining for 30 min at room temperature. Then, crystal violet was
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carefully removed by immersing the plates in tap water. The plates were then air-dried at
room temperature for colony counting, where colonies with more than 50 cells were
counted.
Immunohistochemistry analysis
Hematoxylin and eosin staining of ovarian tumor tissues was performed by UNMC’s
Tissue Science Core Facility to identify tissue areas containing tumor. One core from each
tumor was arranged into a tumor microarray and slides were generated from the
microarray. The resulting slides were stained with antibody directed Mcl-1 using Leica
bond polymer refine detection kit according to manufacturer's instructions (Leica
Microsystems Inc.). Briefly, the ovarian tumor tissue sections were incubated with rabbit
anti-Mcl-1 primary antibody (Santa Cruz Biotechnology, Inc. sc-819). Pictures were
captured by using Coreo Au slide scanner (Ventana Medical Systems Inc.). From each
image, a representative screen shot was captured at 40X magnification. Quantification of
staining was done using these images.
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Chapter 5: Evaluation of small molecule 13-197
Introduction to 13-197
13-197 was originally identified as a small molecule capable of inhibiting growth in
a growth inhibition screen conducted with a panel of cell lines including A549 lung cancer
cells, AsPC-1 pancreatic cancer cells, HT29 colon cancer cells, MDA-MB-231 breast
cancer cells, PC3 prostate cancer cells, SKOV3 ovarian cancer cells and U-2 OS bone
sarcoma cells. 13-197 was shown to induce caspase 3/7 activation in MDA-MD-231, PC3
and HeLa cell lines and PARP cleavage in HeLa cells in a Mcl-dependent manner.126, 127
To further study the apoptotic effects of 13-197, MIAPaCa-2 pancreatic cancer
cells were treated with 13-197 and apoptosis was measured using the live/dead assay
(Figure 1A). Treatment with 13-197 resulted in 4X more apoptosis in treated cells than in

Figure 1: 13-197 blocks cell cycle progression and induces
cell death in MIAPaCa-2 cells. A) Treatment with 13-197 led to
increased apoptosis in MIAPaCa-2 cells as measured by the
live/dead cellular assay. B) Treatment with 13-197 led to an
increase in the number of cells in the G1 phase of the cell cycle
and reduced levels of E2F, PCNA and Cyclin D1. Reproduced
from ref 128
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control cells. Subsequent studies demonstrated induction of cell cycle arrest upon
treatment with 13-197 (Figure 1B, left). These studies also showed reduced levels of the
cell cycle markers E2F, PCNA and Cyclin D1 (Figure 1B, right), demonstrating that 13197 inhibits MIAPaCa-2 cell growth through induction of G1 arrest.128
As the NF-κB pathway is known to control the transcription of genes that regulate
growth, apoptosis and the cell cycle,142, 143 processes which are all affected by 13-197, the
small molecule was screened for activity in this pathway. For the screen, a lung cancer
cell line (A549) that was specifically designed to express firefly luciferase under control of
an NF-κB-driven promoter was used to monitor the activity of NF-κB in response to TNF
(Panomics). Cells were treated with the compounds for 2 h and then TNF was added to
cells to stimulate the NF-κB pathway for an additional 6 h. Under multiplexing conditions
the cells were assayed for viability using AlamarBlue (Ab Serotec) and TNF-induced
IKKβ-mediated NF-κB-driven transcription using the ONE-Glo luciferase system
(Promega). Treatment with 13-197
resulted in a 75% decrease in NF-κBdriven

transcription

compared

to

DMSO-treated cells.
As NF-κB is known to regulate
invasion and metastasis,144 the ability of
13-197 to block invasion and migration
of MIAPaCa-2 cells was also measured
(Figure 2). 13-197 inhibited both the
invasion and migration of MIAPaCa-2
cells by about 50%, demonstrating that

Figure 2: 13-197 inhibits invasion and
migration of cancer cells. Treatment with
13-197 led to decreased invasion and
migration of MIAPaCa-2 cells. Reproduced
from ref 128

13-197 may inhibit both the growth of primary tumors and their metastasis.
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With this building evidence that 13-197 could serve as an inhibitor of viability, cell
cycle progression and invasion and migration of cancer cells, we decided to further
investigate 13-197’s mechanism of action and its effects on cancer cells via its inhibition
of the NF-κB pathway.
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Results
13-197 was identified as an inhibitor of TNF-induced IKKβ-mediated NF-κBdriven transcription in luciferase A549 cells. In a focused, follow-up screen using the same
assay, 13-197 and quinoxaline urea analogs were screened for activity against TNFinduced IKKβ-mediated NF-κB-driven luciferase expression at 20 µM to generate a small
structure activity relationship (Figure 3). The well-studied NF-κB pathway inhibitor

Figure 3: Subset of a focused library screened to identify inhibitors of TNFdriven IKKβ-mediated NF-B activation. Quinoxaline analogs were screened for
activity against the NF-κB pathway at 20 M. The core structure of the analogs
featured in this screen and the positive control parthenolide is given above the graph
and the structures for the quinoxaline analogs are given to the right.
parthenolide122 was used as a positive control. Small molecule 13-197 features furan rings
at the R1 positions and a bromo- substituent at the R2 position. Replacement of the R1
furan rings with pyridine rings (20-185) resulted in negligible loss of activity. Replacement
of the R1 furan rings with a methyl group (20-162) had a greater effect on activity.
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Furthermore, substitution of the bromo- group at the R2 position of analog 20-162 with
hydrogen yielded analog 13-123, which
displayed no activity in the assay.
A follow-up screen against 318
kinases identified IKKβ as a molecular
target of 13-197. The kinase screen
was outsourced to Reaction Biology
Corp.

13-197

was

screened

in

duplicate against 318 kinases. Six
kinases were identified as hits based
on >2 SD (> 95% confidence) from the
mean of the screen (Figure 4). These
kinases

included

ephrin

Figure 4: 13-197 inhibits IKKβ activity. A
follow-up kinase screen identified IKKβ as a
molecular target of 13-197. Reproduced
from ref 128

type-A

receptor 6 (EPHA6), mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4),
IKKβ, never in mitosis A-related kinase 3 (Nek3), serine/threonine protein kinase 25
(STK25) and tropomyosin receptor kinase A (TrkA). The IC50 values were in the low-M
range for four of the six kinases inhibited by 13-197. The kinases TRKA and IKKβ had the
lowest IC50 values at 1.9  0.2 M and 3.0  0.1 M respectively.
As IKKβ phosphorylates IκB upon stimulation with TNF, we hypothesized that
treatment with 13-197 should block IκB phosphorylation. To test this, HEK293 cells were
pretreated with DMSO or 13-197 for 2 h and then stimulated with 20 ng/mL TNF for
increasing times (0, 5, 10, 15, 20, 30, 45, 60, 75, 90 and 120 min) to drive IKKβ activation
and IκB phosphorylation and degradation. Cells were harvested and the cytoplasmic
fraction was probed for phosphorylated and total IκB to measure IKKβ activity (Figure 5).
In DMSO-treated HEK293 cells, stimulation with TNF resulted in phosphorylation of IB
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by the 5 min time point. Thirty minutes after stimulation, most of the IB in the cell had
been

phosphorylated and

degraded

via

phosphorylation-mediated proteasomal

degradation. As IB is a target gene of NF-κB, IκB re-expression was seen 45 min poststimulation. The newly synthesized IκB present at the 45 min time point was again
phosphorylated by IKKβ. In the presence of 13-197, little inhibition of IκB phosphorylation
and degradation was seen at the early time points. A similar pattern to DMSO-treated cells
is seen at the 30 min time point and at 75 minutes post-stimulation re-expression of IκB
is seen. However, a significant reduction in phospho-IκB levels in comparison to DMSOtreated lanes is seen at the latest time points. The results of this experiment suggest that
13-197 does not inhibit the resting form of IKKβ that would persist prior to TNF treatment
but rather inhibits the phosphorylated form of IKKβ that persists approximately 1 h
following TNF stimulation.

Figure 5: 13-197 inhibits phosphorylated IKKβ. HEK293 cells were pretreated
with DMSO or 13-197 for 2 h and then the NF-κB pathway was stimulated by
treatment with 20 ng/mL TNF for the times indicated. In DMSO-treated cells, IκB
is rapidly phosphorylated (5 min) leading to its degradation (30 min). Re-expression
of IκB occurs by the 45 min time point in DMSO-treated cells and persists through
the experiment. This newly synthesized IκB is again phosphorylated. In 13-197treated cells, a similar pattern is seen through the 30 min time point. Again, at later
time points, re-expression of IκB is seen. However, this newly synthesized IκB is
not phosphorylated by IKKβ.
To further test the hypothesis that 13-197 inhibits phosphorylated IKKβ and not
resting IKKβ, we compared the activity of 13-197 to that of the commercially available,
ATP-competitive IKKβ inhibitor TPCA-1118 (Figure 6). As before, cells were pretreated with
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compound (13-197 or TPCA-1) and then stimulated with TNF to drive activation of the
NF-κB pathway. In 13-197-treated cells there is rapid phosphorylation of IκB. However,
when cells are treated with TPCA-1 a different pattern is seen. In cells treated with TPCA1, there is no early phosphorylation of IκB, demonstrating that TPCA-1 inhibits resting,
unphosphorylated IKKβ and thus inhibits the rapid phosphorylation of IκB seen within
minutes of TNF stimulation in DMSO- or 13-197-treated cells. These results further
support the hypothesis that 13-197 preferentially targets phosphorylated IKKβ and

Figure 6: Inhibition of resting IKKβ by TPCA-1 but not 13-197.
IKK was activated by TNF (20 ng/mL) in HEK293 cells
pretreated with vehicle, TPCA-1 or 13-197 (20 M). Cell lysates
were generated at early time points and probed for phospho-IκB,
total IκB and tubulin. Reproduced from ref128
establishes a unique mechanism of action for the small molecule.
Since the knockout of IKKβ has been shown to stall the progression of Kras-driven
pancreatic cancer at PanIN lesions in mice,72 and previous data had shown activity in
pancreatic cancer cell lines,145 we next decided to explore the role of IKKβ in pancreatic
cancer cell lines. RIPA whole cell lysates of Hs766T, MIAPaCa-2, Capan-2, Suit-2 and
AsPC-1 pancreatic cancer cells lines were probed for phosphorylated and activated IKKβ
(Figure 7). Robust phosphorylation of the kinase was seen in all 5 pancreatic cancer cell
lines, suggesting that activation of the kinase indeed may play a role in pancreatic cancer.
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Figure 7: IKKβ is phosphorylated in pancreatic cancer cell lines. Pancreatic
cancer cell lines were probed for phosphorylated and total IKKβ. Under basal
conditions, IKKβ is phosphorylated in pancreatic cancer cell lines. This experiment
was performed with Jacob Contreras.
To test if 13-197 would inhibit the activated IKKβ that was seen in the pancreatic
cancer cell lines, Dr. Vashti C. Bryant and I treated a panel of pancreatic cancer cells with
13-197 and probed lysates for levels of phospho- and total IκB (Figure 8). Treatment with
20 µM 13-197 for two hours resulted in decreased phosphorylation of the IKKβ substrate.
Next, we treated MIAPaCa-2 pancreatic cancer cells with 13-197 and monitored
phosphorylation of IκB upon treatment with increasing doses of 13-197 or increasing
exposure to a single concentration of 13-197 (Figure 9A). Additionally, we assessed the
viability of a panel of cell lines over time using the AlamarBlue assay (Figure 9B and C).
13-197 inhibited IκB phosphorylation and cell viability at low µM-potency.

Figure 8: 13-197 reduces IκB phosphorylation in pancreatic cancer cell
lines. Pancreatic cancer cell lines were treated with 13-197 at 20 µM for 2 hours
and lysates were probed for phosphorylated and total IκB. AsPC1, Capan-2 and
Hs766T immunoblotting performed by Dr. Vashti C. Bryant. Reproduced from ref128
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Given NF-κB’s role in anti-apoptotic signaling,146 we next investigated 13-197’s
ability to induce apoptosis in cancer cells through down-regulation of anti-apoptotic
proteins. To test this, I treated MIAPaCa-2 cells with 13-197 at increasing concentrations
or for increasing periods of time and probed lysates for Bcl-xL, Mcl-1, survivin and XIAP,
which are all known target genes of NF-κB.21, 23-25 Dose-dependent decreases in the levels
of Bcl-xL, survivin, Mcl-1 and XIAP were seen in cells treated with 10 or 20 µM 13-197 for
2 h (Figure 10, left panel). Furthermore, decrease of Bcl-xL, survivin and Mcl-1 levels was
time-dependent with Mcl-1 levels decreasing within 30 min of 13-197 treatment (Figure
10, right panel), suggesting IKKβ may regulate the stability of Mcl-1 via phosphorylation

Figure 9: 13-197 reduces IκB phosphorylation and viability of pancreatic
cancer cells. A) Treatment with 13-197 led to decreased expression of P-IκB in
pancreatic cancer cells. Furthermore, this inhibition of IκB phosphorylation was dose
dependent. Reproduced from ref128 B) Treatment with 13-197 reduced cell viability in
a panel of pancreatic cancer cells. C) Representative dose-response curve with
MIAPaCa-2 cells. Bars represent standard error of the mean for three separate
experiments conducted at least in duplicate.
of the protein. Overall, this data demonstrates that 13-197 down regulates anti-apoptotic
proteins in both dose- and time-dependent manners.
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Due to these promising cell-based results, which demonstrated decreased NF-κBdriven transcription, decreased phosphorylation of IκB, inhibition of phosphorylated IKKβ

Figure 10: 13-197 decrease levels of anti-apoptotic proteins in cancer cells.
Treatment with 13-197 led to decreased expression of anti-apoptotic proteins Mcl-1,
Bcl-xL, XIAP and survivin. Reproduced from ref 128
activity, decreased cell viability and increased apoptosis in cancer cells, small molecule
13-197 was moved into a mouse model of pancreatic cancer by collaborators, namely Dr.
Prakash Radhakrishnan.128 An orthotopic mouse model of pancreatic cancer was used to
investigate 13-197’s anticancer properties in vivo. For this study, MIAPaCa-2 cells were
orthotopically placed in the pancreas of nude mice and mice were allowed to heal after
surgery. Tumors were given 2 weeks to grow and were palpable and the end of this period.
Tumor-bearing mice were randomized and half the animals were treated orally with 150
mg/kg 13-197 in cremaphor daily while the other half was treated with vehicle control. At
the end of 30 days the mice were sacrificed and the tumors weights and volumes were
measured.
Tumor weights and volumes were reduced by 50% in 13-197-treated animals
compared to vehicle-treated mice (Figure 11A). Fewer tumor nodules were seen in other
organs of 13-197-treated animals compared to vehicle-treated animals (Figure 11B),
which is consistent with our cell-based data demonstrating inhibition of MIAPaCa-2 cell
growth and invasion and migration. Proliferation index and microvessel density were
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measured to assess the number of cells dividing in tumors and as measure of
angiogenesis, respectively (Figure 11C and D). A reduction of both, as measured by Ki67 staining and CD31 staining, respectively was seen in 13-197-treated mice compared
to vehicle controls. Tumor tissues were scored by a pathologist (Dr. Subodh Lele) and
decreased inflammation and increased necrosis was seen in 13-197-treated mice (Figure
11E). The levels of 13-197 in the pancreas, liver and serum were determined at the end
of the study with the levels being the highest in the liver. Due to the high levels of 13-197
in the liver, levels of ALT and AST were measured in 13-197- and vehicle-treated mice
(Figure 11F and G). No difference in the levels of these enzymes were seen between 13197- and vehicle-treated mice, indicating an absence of liver toxicity (Figure 11G).
Macroscopic examination of the organs of 13-197-treated and vehicle-treated mice found
no obvious toxicities in 13-197-treated animals. Overall, these studies show that 13-197
is an orally available small molecule that exhibits excellent distribution and reduces tumor
burden and metastases in a mouse model of pancreatic cancer without inducing toxicity.
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Figure 11: Treatment with 13-197 reduces tumor burden and metastases in a
mouse model of pancreatic cancer. A) Tumor weights and volumes in 13-197- and
vehicle-treated mice at the end of the study. B) Number of animals with tumors and
number of tumor nodules found in various organs. C) Ki-67 staining. D) CD31+
staining. E) Inflammation and necrosis scored by a pathologist (Dr. Subodh Lele). F)
13-197 levels in the pancreas, liver and serum 18 h after the last treatment. G) AST
and ALT levels measured in mice at the end of the study. (**P < 0.05). The work
depicted in this figure was performed by Dr. Prakash Radhakrishnan and
collaborators from Tony Hollingsworth’s lab and Dr. Subodh Lele. Reproduced from
ref128
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On-going studies with 13-197
As other NF-κB pathway inhibitors have shown an ability to chemosensitize cells
to treatment with the clinical therapeutics gemcitabine114,

115

and paclitaxel,98 we are

investigating the ability of 13-197 to synergize with these compounds in pancreatic cancer
cells. To accomplish this goal, I have determined IC50 values for gemcitabine and
paclitaxel in a panel of pancreatic cancer cell lines (Capan-2, MIAPaCa-2 and SUIT2 cells)
for which 13-197 sensitivity has already been established (Figure 9, this chapter). A
representative dose-response graph for MIAPaCa-2 cells is shown (Figure 12). MIAPaCa2, Capan-2 and SUIT-2 cells were sensitive to the clinical inhibitor paclitaxel with IC50s in

Figure 12: IC50 values for paclitaxel and gemcitabine in five pancreatic cancer
cell lines that are sensitive to 13-197 treatment. A) IC50 values for paclitaxel and
gemcitabine for a panel of 5 pancreatic cancer cell lines. Representative dose
response curves for paclitaxel and gemcitabine in MIAPaCa-2 pancreatic cancer
cells.
the low (Capan-2 and MIAPaCa-2) or mid (SUIT-2) nM range while all displayed IC50s to
gemcitabine in the mid µM range. Interestingly, the two cell lines that are not sensitive to
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treatment with paclitaxel and gemcitabine, AsPC-1 and Hs766t, above 100 µM are
sensitive to 13-197 at approximately 17 and 14 µM respectively,128 suggesting 13-197 may
serve as a viable therapeutic for the treatment of pancreatic cancer resistant to current
clinical inhibitors.
Using these IC50 values as starting points, we will treat the cells lines with 13-197
and gemcitabine, 13-197 and paclitaxel or 13-197, gemcitabine and paclitaxel in
combination at 5X their IC50s, their IC50s and subIC50 concentrations of the clinical inhibitors
in matrix format to test for possible synergism. CI values will be derived from pancreatic
cancer cell treatments at the above concentrations for 72 hours. Cell viability will be
determined via AlamarBlue assay and the fraction of cells dead for each treatment will be
calculated. These values will be used to calculate combination index (CI) values using
CalcuSyn and the Chou-Talalay method for calculating CI values. Using this method, a
combination index will be calculated for a combination treatment based on the fraction of
cells affected (fraction dead) by a particular treatment. CI values below 1 indicate
synergism. Additive effects are indicated by a CI value of 1. A value above 1 indicates
antagonism.147 As other NF-κB pathway inhibitors have shown synergism with
gemcitabine and paclitaxel,80, 82, 114, 115 we expect to see the same with 13-197.
Conclusions
The work presented in this chapter provides evidence that IKKβ is phosphorylated
and activated in pancreatic cancer cells which leads to the phosphorylation of IB and
subsequent activation of the NF-B pathway. Treatment of HEK293 cells with the
quinoxaline urea analog 13-197 results in decreased phosphorylation of IB an hour
following stimulation with TNF, suggesting 13-197 targets a phosphorylated, activated
form of IKKβ but not resting IKKβ. In pancreatic cancer cells, 13-197 targets IKKβ to
regulate transcription through the IKKβ/IB/NF-B pathway, resulting in decreased
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expression of anti-apoptotic proteins Bcl-xL, Mcl-1, survivin and XIAP and decreased
viability of cancer cells. Furthermore, 13-197 exhibited low-µM potency in two cell lines
(AsPC-1 and Hs766T)128 that are resistant to treatment with paclitaxel and gemcitabine.
Lastly, work with collaborators has shown that 13-197 reduces tumor burden in a mouse
model of pancreatic cancer without inducing toxicities associated with known IKKβ
inhibitors. Further studies with the small molecule will be aimed at further refining the small
molecule’s mechanism of action by identifying the form of IKKβ inhibited by 13-197.
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Chapter 6: Evaluation of small molecule 25-4
Results
As mentioned previously, the small molecule 25-4 was designed to feature the
same -methylene--butyrolactone motif found in the natural product parthenolide, which
has been shown to have activity against the NF-κB pathway despite its limited success in
clinical trials.122, 124 The available SAR with parthenolide analogs clearly shows that the
Michael acceptor in the -methylene--butyrolactone is critical for activity against the NFκB pathway.117
Here we generated a biased library that features the -methylene--butyrolactone
core and tested this library for activity against TNF-induced IKKβ-mediated NF-κB-driven
transcription activation again using our cell-based luciferase assay (Figure 1). At 20 µM,
small molecule 25-4 displayed high activity in the screen, inhibiting NF-κB-driven
transcription by nearly 75%. Reduction of the double bond of the ,β-unsaturated lactone
resulted in compound 25-18, which showed no activity in the screen. 28-090, which is an
acyclic analog of 25-4, showed reduced activity compared to 25-4, suggesting the ,βunsaturated lactone and rigidification of the Michael acceptor are necessary for the high
activity of 25-4. Substitution of the hydrogen at the R1 position with a methyl group resulted
in small molecule 28-097C, which showed activity comparable to that of 25-4 in the assay.
28-097A, which is an acyclic version of 28-097C, showed reduced activity in the assay,
again indicating that rigidification of the Michael acceptor is a favorable feature.
Compounds 28-131, 28-138 and 28-171 feature the same hydrogen at the R1 position as
25-4 but feature substitutions at the R3, R2 and R4, and R5 positions, respectively. 28131 which features the iodo- substitution at R3 showed a moderate decrease in activity
while substitution with methyl groups at the R2 and R4 positions (28-138) or a phenyl
substitution at the R5 position (28-171) resulted in activity comparable to that of 25-4.
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Overall, these SAR studies showed that the presence and rigidification of the Michael
acceptor in the ,β-unsaturated lactone were key for activity.
To confirm that rigidification indeed resulted in increased activity and to determine

Figure 1: Novel -methylene--butyrolactone analogs exhibit activity against
the NF-B pathway. Inhibition of TNF-induced IKK-mediated NF-B activity by the
-methylene--butyrolactone analogs. The core structure of the compounds featured
in the focused library of -methylene--butyrolactone analogs and parthenolide is
above the graph while each analog’s structure can be found to the right. Library
synthesized by Dr. Sandeep Rana.
if the Michael acceptor is critical for activity, we further compared the activity of 25-4, the
reduced compound that lacks the Michael acceptor (25-18) and the acyclic compound 28090 to that of parthenolide and a reduced parthenolide analog that lacks the Michael
acceptor (Figure 2A). Consistent with previous reports, parthenolide showed more than
95% inhibition while the reduced version was much less active and only exhibited
approximately 20% inhibition, demonstrating that the Michael acceptor in parthenolide is
critical for NF-κB inhibitory activity (Figure 2B).11 Similarly the reduced analog 25-18 that
lacks the Michael acceptor was >10-fold less active (approximately 5% inhibition) than its
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corresponding analog with the Michael acceptor (25-4). Importantly the acyclic analog with
the Michael acceptor (28-090) was approximately 2-fold less active than the cyclized
version, suggesting that rigidification indeed increases activity against the NF-κB pathway.
In a follow-up dose-response
study, 25-4 had low M (IC50 ~
4 M) inhibitory activity in the
TNF-induced
mediated
transcription

IKKβNF-κB-driven
activity

assay

(Figure 2C). Overall, these
studies identified compound
25-4 with the -methylene-butyrolactone as a potent NFFigure 2: Focused SAR with parthenolide, reduced
parthenolide and 3 analogs. A) Structure of
parthenolide, reduced parthenolide and 3 analogs B)
Evaluation of the above inhibitors in the TNF-induced
IKKβ-mediated NF-κB-driven transcription assay
demonstrates the importance of the Michael acceptor
and rigidification C) Dose-dependent inhibition of NFκB activity by 25-4. 25-4, 25-18 and 28-090
synthesized by Dr. Sandeep Rana.

κB inhibitor. Like parthenolide,
the NF-κB inhibitory activity of
25-4 requires the Michael
acceptor.

Additionally,

rigidification of the Michael

acceptor of 25-4 increases its NF-κB inhibitory activity.
We next used click chemistry, which is emerging as a powerful technique for
determining the targets of covalent small molecules,148 to determine if 25-4 does indeed
bind irreversibly to the parthenolide targets IKKβ and NF-κB.122, 130 For these studies, the
25-4 analog 31-036 (Figure 3), which is 25-4 with an alkyne handle at the R1 position, was
used. The alkyne handle on 31-036 reacts with the azide handle on TAMRA-azide to
covalently link the two, thereby tagging 31-036 and its target proteins with a fluorescent
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rhodamine tag. Recombinant IKKβ and NF-κB were incubated with 31-036 for 1 h at room
temperature. Rhodamine azide and click reagents were added to the reaction mixture and
incubated for an additional hour. At the end of the second hour the mixture was subjected
to SDS-PAGE and the gel was imaged using the Typhoon 9410 Variable Mode Imager, an
imager that produces digital images of fluorescent samples. The data summarized in
Figure 3A shows fluorescent bands at molecular weights that correspond to IKKβ and NFκB (with a 14 amino acid C-terminal truncation), demonstrating that 31-036 is a covalent
inhibitor of IKKβ and NF-κB.

Figure 3. 25-4 binds IKKβ and NF-κB to block IKKβ-mediated NF-κB activation.
A) Schematic of click chemistry used to demonstrate covalent binding of 31-036 to
IKKβ and NF-κB. B and C) Inhibition of IKKβ kinase activity determined by Western
blot analysis in MBA-MD-231 breast cancer cells and MIAPaCa-2 pancreatic cancer
cells. 31-036 synthesized by Dr. Sandeep Rana.
To determine if covalent binding to IKKβ results in the inhibition of the kinase
activity of IKKβ, MBA-MD-231 breast cancer cells were incubated with 25-4, 25-18, 28090, 28-097A and 28-097C (Figure 3B). The cells were lysed and the proteins were
separated by SDS-PAGE, transferred to a membrane and probed with total and phosphoIB antibody. Since IB is a substrate of IKKβ, inhibition of the kinase activity of IKKβ
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should result in reduced IB phosphorylation. Indeed we observed complete inhibition of
IB phosphorylation in cells treated with 25-4 but no inhibition of IB phosphorylation
in cells treated with the reduced compound 25-18 that lacks the Michael acceptor. The
acyclic analog 28-090 showed partial inhibitory activity, which confirms that rigidification
of the Michael acceptor indeed results in increased inhibition of IKKβ. Furthermore, 28097C showed activity while its acyclic version, 28-097A, did not, supporting the
observation that rigidification of the Michael acceptor is required for activity and confirming
the results of our luciferase assay.
Studies with 25-4 demonstrated that the small molecule inhibits phosphorylation
of IκB in a dose-dependent manner in MIAPaCa-2 cells (Figure 3C). Cells were
incubated with increasing doses of 25-4 or 25-18 for 2 h. Cells were harvested and
immunoblotting with anti-phospho- and total IκB antibodies was performed. 25-4
treatment, but not 25-18 treatment, reduced levels of IκB phosphorylation, providing
further evidence that 25-4 targets IKKβ while 25-18 does not display activity.
To determine if inhibition of the IKKβ-NF-κB pathway translates to anticancer
activity, MDA-MB-231 and MIAPaCa-2 cancer cell lines were subjected to increasing
concentrations of the IKKβ inhibitors for 3 days and the viability of the cells was assessed
using PrestoBlue dye. The IC50 values for the IKKβ inhibitors were derived by curve fitting
the data. 25-4 showed dose- and time-dependent inhibition of cancer cell growth while 2518 did not (Figure 4A and 4B) again demonstrating that the Michael acceptor is critical for
anticancer activity. Furthermore, we subjected a panel of cancer cell lines to treatment
with 25-4, 25-18 and three previously reported IKKβ inhibitors (13-197, Bayer VIII and
TPCA-1). Importantly, the growth inhibitory activity of 25-4 was comparable to known IKKβ
inhibitors (Table 1).

62

Figure 4: 25-4 decreases cancer cell growth. Dose-response studies with 254 and 25-18 in A) MDA-MD-231 and B) MIAPaCa-2 cells demonstrate that 25-4
dose- and time-dependently reduces cell viability of cancer cells while the small
molecule lacking the Michael acceptor (25-18) does not.
IKKβ inhibitor

Cancer cell line

IC50 (M)

25-4

MIAPaCa-2 (Pancreas)

1.2 ± 0.2

25-4

MDA-MB-231 (Breast)

5.6 ± 0.9

25-4

A2780 (Ovarian)

2.3 ± 1.4

25-4

A2780 Cisplatin-resistant (Ovarian)

3.01 ± 1.1

13-197

MIAPaCa-2 (Pancreas)

1.9 ± 0.6

13-197

MDA-MB-231 (Breast)

2.1 ± 0.2

Bayer VIII

MIAPaCa-2 (Pancreas)

7.3 ± 0.7

Bayer VIII

MDA-MB-231 (Breast)

8.4 ± 1.2

TPCA-1

MIAPaCa-2 (Pancreas)

1.8 ± 0.7

TPCA-1

MDA-MB-231 (Breast)

6.6 ± 1.9

Table 1: Inhibition of cancer cell growth by 25-4 and known IKKβ inhibitors. 254 inhibits the growth of cancer cells with IC50 values comparable to those of
commercially available IKKβ inhibitors. IC50 values for 13-197 in MDA-MB-231 cells
and IC50 values for Bayer VIII and TPCA-1 were determined by Smitha Kizhake.
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Tian Zhou next helped us determine the ability of 25-4 and 25-18 to block colony
formation using a clonogenic assay. Cells were sparsely plated and allowed to grow in the
presence or absence of 25-4 or 25-18 for 7 days. Colonies were then stained using crystal
violet and quantified (Figure 5A and B). In plates treated with 25-4 we observed a dosedependent decrease in the number of colonies while we saw no such effect with 25-18.

Figure 5: 25-4 inhibits colony formation and induces caspase 3/7 activation in
cancer cells. (A and B) Dose-dependent effects on colony formation of cervical
cancer cells (HeLa) by 25-4 and 25-18. (C) Caspase 3/7 activity induced by 25-4,
cisplatin and the combination in SKOV3 ovarian cancer cells. Tian Zhou performed
the clonogenic assay pictured in A and B.
As the NF-κB pathway controls the transcription of many genes that regulate
apoptosis, we evaluated the ability of 25-4 and 25-18 to induce caspase 3/7 (Figure 5C)
and PARP cleavage (Figure 6), two key events during apoptosis,149 in cancer cell lines.
Furthermore, we studied the ability of 25-4 to sensitize cells to treatment with cisplatin as
platinum-based chemotherapeutics are the first line of treatment for many cancers,
including ovarian cancer.150 In cells treated with 25-4 we observed modest induction of
caspase 3/7 cleavage by itself and increased induction of caspase 3/7 cleavage in the
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presence of a cisplatin. This is consistent with reports that implicate activation of NF-κB in
chemoresistance. We also observed decreased/cleaved PARP in cells treated with 25-4.
Importantly we observed no such effects in 25-18-treated cells. These studies clearly
demonstrate that the biological effects induced by 25-4 are through the Michael acceptor
functionality.
Due to these promising cell-based results, we next collaborated with investigators

Figure 6: Induction of PARP cleavage by 25-4. Treatment with 25-4 led to PARP
cleavage in MIAPaCa-2 (pancreatic), SKOV3 and A2780 (ovarian) and HeLa
(cervical) cancer cell lines.
at Henry Ford Hospital to investigate if these anticancer effects in cell lines translate to
mouse models. To do this, two studies were conducted. One aimed to determine the
optimal doses of 25-4 and cisplatin that are required to inhibit tumor growth in an orthotopic
ovarian cancer model and the second tested 25-4’s ability to synergize with cisplatin. For
each, A2780 ovarian cancer cells were injected into the peritoneal cavity of nude mice and
the tumors were allowed to establish. On day 3 of the first study, mice were dosed with
one of three doses of 25-4 (1, 2.5 or 5 mg/kg given 5 days a week for 4 weeks) or one of
two doses of cisplatin (2 or 4 mg/kg cisplatin given on days 5, 9, 14, and 21). In a
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preliminary metabolism study conducted in mice, the plasma concentration of parthenolide
was 0.112 µM one hour following oral dosing of 4 mg/kg of the drug.124 As the molecular
weights (248.317 g/mol and 215.21 g/mol, respectively) and potency against TNFinduced IKKβ-mediated NF-κB activity of parthenolide and 25-4 are comparable and the
small molecules are expected to exert their effects similar mechanisms of action, we
choose to treat mice with comparable doses of 25-4 (1, 2.5, and 5 mg/kg). Though PK
studies were not conducted with 25-4, the goal of this study was just to establish that 254 exhibits anticancer properties in mice and is non-toxic in mice at a therapeutic dose. At
the end of the study, the mice were sacrificed and the tumor weights determined (Figure
7). As other IKKβ inhibitors have shown toxicities in mice, it is important to note that no
overt toxicity was observed in the mice treated with 25-4 (aside from blocked bowels at

Figure 7: 25-4 decreases A2780 tumor weight alone and in combination with
cisplatin in a mouse model of ovarian cancer. Dose-dependent effects on A2780
ovarian cancer cell growth by 25-4, cisplatin and the combination in an orthotopic
model of ovarian cancer. P values were calculated only for 2.5 mg/kg 25-4
compared to vehicle and the combination of 25-4 and cisplatin compared to each
single treatment. Mouse studies performed by Calvin Tebbe, Adnan R. Munkarah
and Ramandeep Rattan, Josephine Ford Cancer Center.
the highest dose). Additionally, approximately 40% reduction in tumor weights in mice
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treated with 25-4 (5 mg/kg) and 25% reduction of tumor weights in mice treated with
cisplatin (2 mg/kg) were observed when compared to controls. To determine if 25-4 could
chemosensitize ovarian tumors to cisplatin, a follow up study in which mice were treated
with 2.5 mg/kg of 25-4 (5 days a week for 4 weeks) and 2 mg/kg of cisplatin (on days 5,
9, 14 and 21) was performed. The combination resulted in 60% reduction in tumor weights
compared to the controls. These studies clearly demonstrate that 25-4 by itself has
anticancer activity and the ability to chemosensitize ovarian tumors to cisplatin.
Next,

with

the

help

of

Dr.

Prakash

Radhakrishnan we performed immunohistochemical
analysis of the excised tumor tissue (Figure 8).
Immunohistochemistry revealed that treatment with
25-4, cisplatin and the combination reduced levels of
Mcl-1 staining by over 66%.
On-going projects with 25-4
To further validate that 25-4 binds to IKKβ and
p65 to drive cancer cell death, we are conducting a
series of experiments using click chemistry to
determine the targets of 25-4. As the small molecule
is designed to target surface-exposed cysteine
residues, we first incubated the small molecule at 20

Figure 8: 25-4 treatment
reduces Mcl-1 levels in an
orthotopic model of ovarian
cancer. Tumor-bearing mice
were treated with vehicle, 254, cisplatin or the combination
and immunohistrochemistry
studies using Mcl-1 antibodies
were performed on the
excised
tumor
tissues.
Immunohistochemistry
performed by Dr. Prakash
Radhakrishnan.

µM with a panel of cancer cell lines including luciferase A549 cells, which is the cell line
we used to measure TNF-induced IKKβ-mediated NF-κB-driven transcription activity,
MBA-MD-231 cells, HeLa cells and SKOV3 cells for 1 h. Cells were harvested and 200 µg
of whole cell lysate was incubated with TAMRA-azide and additional click reagents for 1
h. Samples were resolved by SDS-PAGE and fluorescent bands were imaged using the
Typhoon (Figure 9). At this concentration, time point and Typhoon setting, the luciferase
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A549 cells have the most distinct banding pattern but similar bands are seen in the other
cell lines.

Figure 9: 25-4 targets proteins in a panel of cancer cell lines. Luciferase A549,
MDA-MB-231, HeLa and SKOV3 cells were incubated with 31-036 at 20 µM for 1
h and harvested. Click chemistry was performed on 200 µg protein with 5-TAMRAazide.
Moving forward, we characterized the bands (“click signature”) seen in MDA-MB231 cells as we had accumulated growth and IKKβ inhibition data in these cells. First we
performed a dose-response study with 31-036 and MDA-MD-231 cells (Figure 10, left)
and saw that 31-036 binding to each of its targets in MDA-MD-231 cells was indeed dosedependent. Next, we wanted to see how quickly 31-036 would bind to its targets in cells.
To test this, we treated MDA-MD-231 cells with 31-036 for 5 min, harvested cells and
performed click chemistry (Figure 10, right). In MDA-MD-231 cells, 31-036 binding to
targets occurs within 5 min. Overall, these studies demonstrate that binding of 31-036 to
target proteins in cells is dose-dependent and rapid.
To ensure that 25-4 and 31-036, which again is 25-4 with an alkyne handle at the
R1 position, indeed bind the same targets in cells, a competition assay with the two small
molecules was performed in MDA-MD-231 cells. MDA-MB-231 cells were incubated with
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31-036 or 25-4 for 1 h or with 25-4
for 1 h followed by 31-036 for 1 h.
Cells were harvested and click
chemistry was performed (Figure
11).

Pre-incubation

with

25-4

decreased the fluorescent signal
produced by 31-036 following click
chemistry with 5-TAMRA azide,
indicating the small molecules
indeed bind the same targets
within MDA-MB-231 cells.
To

further

study

and

Figure 10: 25-4 binds to targets in MDA-MB231 cells dose-dependently and rapidly. MDAMB-231 cells were treated with the indicated
concentrations of 31-036 for the indicated times,
harvested and click chemistry with 5-TAMRA
azide was performed on 200 µg protein. Left) 31036 binds dose-dependently to targets within 231
cells and (Right) binds within 5 min of treatment.

identify all the proteins targeted by 31-036, click chemistry will be performed with 31-036
and a trifunctional TAMRA-biotin-azide. Cells will be treated with 31-036 and harvested,
cell lysates will be incubated with TAMRA-biotin-azide and click chemistry will be
performed. Pulldown of biotin with streptavidin beads will be performed to capture
TAMRA-biotin-azide in complex with 31-036-targeted proteins. These proteins will then be
sent out for identification via mass spectrometry (Figure 12 outlines these studies).
Towards this goal, we have performed click chemistry with both 31-036 and TAMRAazide, which has been used in all our previous studies, alongside click chemistry with 31036 and the trifunctional TAMRA-biotin-azide (Figure 13). These studies show that click
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chemistry with the TAMRA-biotin-azide has been optimized and the click signature with
the trifunctional TAMRA-biotin-azide replicates the signature seen with TAMRA-azide
(Figure 13).
Thus far, our studies with 25-4, 31-036 and click chemistry have demonstrated that
31-036 binding to targets within cells is
dose-dependent and rapid and that the
small molecule indeed binds the same
targets as 25-4. Moving forward, we will use
a combination of click chemistry and biotin
pulldowns to determine the targets of 31036, including which form(s) of IKKβ is
targeted

by

the

small

molecule.

Furthermore, we will conduct SAR studies
to determine which structural changes to
the scaffold can be made to increase
specificity towards one target or another to

Figure 11: 25-4 and 31-036 bind
similar targets in MDA-MB-231 cells.
231 cells were treated with 31-036 or
25-4 for 1 h or with 25-4 for 1 h followed
by incubation with 31-036 for 1 h. Click
chemistry was performed on 200 µg
protein of resulting lysate. Preincubation with 25-4 reduces the
intensity of the click signature of small
molecule 31-036.

characterize the phenotypic consequence of inhibiting each target of 31-036 and to
explore which effects of the small molecule are through inhibition of IKKβ and which effects
can be attributed to off-target interactions.
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Figure 12: Schematic of on-going click chemistry studies. Cancer cells will be
incubated with 31-036 to allow the small molecule to bind its targets in cell lysates
(or intact cells). Next, lysate will be incubated with the trifunctional TAMRA-biotinazide to label 31-036 with fluorescent rhodamine and biotin. The biotin probe now
covalently linked to target proteins will be pulled down using streptavidin beads.
Following pull down, samples will be run on SDS-PAGE and fluorescent bands will
be imaged using the Typhoon to confirm pull down of trifunctional azide. Bands will
be excised or tryptic digestion will be performed on protein attached to beads and
protein targets will be sent for identification via mass spectrometry.

Figure 13: Click chemistry with TAMRA-azide and TAMRA-biotin-azide in cells
and with pure p65 protein. The click signature for TAMRA-azide and TAMRA-biotinazide is similar in cells and with pure protein. Again, this p65 has a 14 amino acid Cterminal truncation, resulting its reduced molecular weight.
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Conclusions
A mechanism-based screen with a focused library of -methylene--butyrolactone
containing-analogs led to the identification of 25-4 as a potent inhibitor of TNF-induced
IKKβ-mediated NF-κB-driven transcription activation. SAR studies revealed that
rigidification of the -methylene--butyrolactone increased the activity of the small
molecule. Additionally, reduction of the Michael acceptor in 25-4 yielded 25-18, which was
inactive in all assays it has been tested in. Our studies also showed that 25-4 binds
covalently to both IKKβ and NF-κB. Furthermore, 25-4 had anticancer activities that are
comparable to known IKKβ inhibitors and sensitizes SKOV3 ovarian cancer cells to
treatment with the clinical therapeutic cisplatin. 25-4 inhibited tumor growth by itself and
in combination with cisplatin in an orthotopic ovarian cancer model to reduce tumor
burden. Furthermore, treatment with the small molecule resulted in reduced levels of Mcl1, which is in line with data seen with other IKKβ and NF-κB inhibitors. Future studies with
25-4 will be aimed at determining the forms of IKKβ targeted by the small molecule,
identifying the other targets of 25-4 and building specificity onto the small molecule’s core.
Importantly, 25-4 is easy to modify and is a suitable starting compound for the extensive
SAR studies required to identify compounds with improved biological activity, specificity
and drug-like properties.
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Chapter 7: Drug discovery and target validation, discussion of results and future
directions and closing perspectives
Drug discovery and target validation
Due to the NF-κB pathway’s implication in cancer, our lab initiated two drug
discovery projects centered on identifying inhibitors of this pathway. Many lines of
evidence caused us to pursue the NF-κB pathway as a target, including the mounting
proof that the pathway plays a key role in K-ras-driven cancers72, 74 and is constitutively
activated in cancers either by signaling from the tumor microenvironment or genetic
aberrations.58, 151 Furthermore, tissue specific deletion of pathway members has shown
much promise in animal-models of disease68, 72-74, 91 and research suggests inhibition of
this pathway could sensitize cancer cells to clinical chemotherapeutics such as paclitaxel,
cisplatin and gemcitabine.82, 98, 110, 114, 115
Small molecule screening typically involves the use of one of two types of
screening strategies: either target/pathway-based screening (such as a kinase assay) or
phenotype-based screening, which allows evaluation of a small molecule within cells (such
as a screen for decreased angiogenesis).152 To begin searching for small molecule
inhibitors of the NF-κB pathway, we chose a target-based screening strategy in which two
libraries of small molecules were tested separately in a luciferase assay that monitored
TNF-induced IKKβ-mediated NF-κB-driven transcription in cells. Though this screen
allowed us to identify inhibitors that targeted a member of the TNF/IKKβ/NF-κB pathway,
small molecules identified by assessing a particular target are very likely to interact with
other proteins in cells and to affect other signaling pathways that may have phenotypic
consequences in cells.
To further test a small molecule for specificity towards a particular target, multiple
experiments can be performed. These include genetic modification of a target protein in
cells to assess if deletion of the protein reproduces the same phenotype as inhibition of
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the protein by the small molecule, overexpression or mutation of the protein to drive
resistance to the small molecule or underexpression of the protein to drive sensitivity to
the small molecule.152 Additionally, rescue experiments that can outcompete the effects of
a small molecule can also be performed to assess off-target effects of a small molecule.153
Furthermore, affinity methods can be used to assess the binding of small
molecules to targets in cells. With this approach, it is assumed that the protein that binds
a given small molecule with the highest affinity is the most likely mediator of the biological
effect of the small molecule in cells. Furthermore, this method usually requires that 1) the
target protein of a small molecule is abundant in cells or tissues and 2) the small molecule
is still capable of interacting with its target when attached to resin or biotin, for example,
in the case of affinity chromatography,154 or a reactive handle, in our case of click
chemistry.
Lastly, mechanistic-based evaluation of a small molecule’s activity can be
performed. For example, inhibition of substrate phosphorylation by a kinase can be used
to validate inhibition of kinase activity.
With these principles in mind, a ‘screening cascade’ can be developed to outline
the biological assays that are required to validate the target of a small molecule. Figures
1 and 2 give an overview of the assays that were performed to validate IKKβ inhibition by
13-197 (Figure 1) and 25-4 (Figure 2). In the following discussion, I will touch on each
experiment conducted with the small molecules and outline how each experiment provides
evidence that IKKβ is targeted by these small molecules. Furthermore, I will suggest future
experiments that will be performed to further validate the target of these small molecules
and investigate possible off-target effects of the compounds. It is important to note that
this ‘screening cascase’ like most is specific to a target of interest (IKKβ), which limits the
information given regarding off-target effects of compounds 13-197 and 25-4.
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Figure 1: Screening cascade for small molecule 13-197. 13-197 was identified as
an inhibitor of TNF-induced IKKβ-mediated NF-κB-driven transcription. Follow-up
studies indicate that the small molecule is an inhibitor of IKKβ. Future studies will be
aimed at validating IKKβ as a target and assessing off-target effects of 13-197.
Validating the targets of small molecule inhibitors and RNAi
Many of the suggested experiments for determining off-target effects of the novel
small molecules 13-197 and 25-4 include the use of RNAi or the genetic knockout or
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modification of IKKβ. It is important to remember that although pharmacological inhibition,
RNA interference and genetic knockout are all complementary methods for assessing the
phenotype caused by the loss of a protein’s activity, these methods each have their own
benefits and limitations. For example, small molecules can be costly and time-consuming
to develop but their rapid induction of activity can prevent compensation by redundant
pathways in cells. Additionally, they allow the probing of a specific function of a protein
(kinase activity or a protein-protein or protein-DNA interaction) without abrogating all
functions of the protein (a scaffolding function in the instance of kinase inhibition). RNAi
interference and genetic knockout, on the other hand, can be more selective but long-term
loss of a protein may allow for compensation and will result in the loss of all functions of a
protein.153 Furthermore, it is key to remember that each method requires its own validation.
Here I will briefly touch on validation techniques for small molecule inhibitors and RNAi
approaches.
In the case of small molecules, SAR studies are required to demonstrate that
modifying substituents of a core structure leads to a range of potencies against a target of
interest. Furthermore, an analog with a very similar scaffold but substituent change that
renders it inactive may need to be developed as a negative control (reduced 25-4 analog
25-18, for example). Additionally, a small molecule with a very different structure but same
target and potency for that target can be selected as a positive control. As unrelated core
structures are expected to have different off-target effects, comparison of the phenotype
induced by this independent positive control and a novel small molecule under validation
may give insights into target-independent effects. Lastly, rescue experiments involving the
expression of a kinase, for example, that is resistant to an inhibitor of interest can be
performed to study off-target effects. Small molecules should also display dosedependency153 as this demonstrates saturatable inhibition of a target.
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RNAi experiments also require validation and careful consideration. siRNA, for
example, should be designed after careful analysis of the mRNA sequence being targeted
to assure targeting of a desired isoform and targeting of a sequence that has little similarity
to other mRNAs. Again, causality can be confirmed with siRNA. Firstly, a combined pool
of siRNAs can be used to target a protein of interest. This minimizes off target effects in
two ways. This allows the use of small concentrations of each siRNA, minimizing the offtarget effect of each but giving efficient reduction in protein production. Furthermore, as
each siRNA’s off-target effects are sequence, and not necessarily target specific, the use
of two independent siRNAs to demonstrate the same phenotype upon target repression
will also establish causality.153
Additionally, controls such as mock transfection should be performed to control for
use of transfection reagent. Also, reduction of mRNA should be monitored using RT-PCR
and loss of protein should be verified by Western blot. Lastly, rescue experiments can also
be performed with siRNA. Here, the expression of an RNAi-resistant transgene can be
used to rescue the phenotype.153
Additionally it is important to keep in mind that each method may result in a
different phenotype, making it difficult to draw exact correlations between pharmacological
inhibition and genetic inhibition.153 For example, if IKKβ’s role as a member of the IKK
complex (and not just as a catalytic subunit of the complex) is key for the protein’s activity
in some biological process, inhibition of the protein using a pharmacological agent such
as 13-197 or 25-4 may not affect its function in this particular pathway. However, loss of
IKKβ through RNAi or genetic knockout may induce a phenotype dependent on the loss
of IKKβ function as a scaffold. To test if IKKβ plays a scaffolding role, catalytically inactive
IKKβ can be expressed in RNAi-targeted to cells to rescue the phenotype induced by loss
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of IKKβ protein but not enzymatic activity. This phenotype should mirror that of
pharmacological inhibition of the kinase.

Figure 2: Screening cascade for small molecule 25-4. Like 13-197, 25-4 was
identified as an inhibitor of TNF-induced IKKβ-mediated NF-κB-driven transcription.
Follow-up studies indicate that the small molecule targets IKKβ and p65. Future
studies will be aimed at validating IKKβ and p65 as targets and will identify additional
cellular targets of 25-4 using click chemistry.
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Discussion of results presented in this dissertation
In the previous two chapters, I have introduced two novel small molecule inhibitors
of IKKβ, 13-197 (Chapter 5) and 25-4 (Chapter 6), and have shown their promise as
potential therapeutics for the treatment of cancer as single agents or in combination with
clinical therapeutics (Figures 5.1, 5.2, 5.9, 5.10, 5.11, 6.4. 6.5, 6.6, 6.7 and 6.8 on pgs 42,
43, 50, 51, 53, 62, 63, 64, 65 and 66, respectively) In this final chapter, I will further expand
upon the results presented for each small molecule and discuss how the effects of 13-197
and 25-4 correlate with the effects of genetic or pharmacological inhibition of the NF-κB
pathway by others. Furthermore, I will touch upon the limitations of the work presented in
this dissertation and discuss future experiments that could be performed to strengthen
and further support our conclusions. I will discuss the implications of the work presented
here and the newly published crystal structure of phosphorylated and non-phosphorylated
human IKKβ protomers and conclude with my perspectives regarding the development of
small molecule inhibitors of IKKβ.
Hit identification of and SAR studies with 13-197 and 25-4
Small molecules 13-197 and 25-4 contain a quinoxaline core and a lactone motif,
respectively (Figure 3.7 pg 35). These two structures can be considered “privileged
structures” as the quinoxaline core serves as a scaffold in a wide variety of molecules with
biological activity and molecules containing -methylene--butyrolactones have been
used for the treatment of a variety of indications.129, 131 As such, chemists in the laboratory
designed two small molecule libraries: one containing analogs featuring each structure.
My work with small molecule 13-197, which had been identified as an inhibitor of
TNF-induced IKKβ-mediated NF-κB-driven transcription by Dr. Vashti C. Bryant in a
large primary screen (data not shown), began with studies focused on determining
structure activity relationships for 13-197 and related quinoxaline analogs (Figure 5.3 pg
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45). To perform this study, a focused subset of quinoxaline urea analogs was tested again
for activity specifically against TNF-induced IKKβ-mediated NF-κB-driven transcription
of firefly luciferase in our lung adenocarcinoma cell line genetically engineered to express
firefly luciferase from a promoter containing a kB element. This study was performed to
assess inhibition of NF-κB activity for two reasons. The first of these reasons is that
inhibition of TNF-induced IKKβ-mediated NF-κB-driven transcription of firefly luciferase
would report on small molecule activity towards the NF-κB pathway only. Assuming offtarget effects of 13-197 and 25-4 did not induce alterations in transcription or translation
of firefly luciferase or the small molecules did not target firefly luciferase itself, the effects
of decreased luciferase activity could be attributed solely to modulation of the NF-κB
pathway. Secondly, inhibition of NF-κB-driven firefly luciferase transcription at varying
degree of potencies by multiple small molecules with a similar core but differing
substituents establishes causality,153 further confirming that inhibition of the NF-κB
pathway by 13-197 (and 25-4, for that matter) was indeed due to inhibition of an NF-κB
pathway member. For studies with 25-4 (Figure 6.1 pg 58), the luciferase assay was used
first to identify 25-4 as a small molecule inhibitor of an NF-κB pathway member (as 13197 had been identified by Dr. Vashti C. Bryant). Follow-up SAR studies using the
luciferase assay gave insights into the key structural features of the small molecule and
its analogs (Figure 6.2 pg 59).
The SAR studies identified substituents key for the activity of 13-197 and 25-4. For
example, the presence of a five- or six-membered ring at the R1 positions of 13-197 was
key for its activity (Figure 5.3 pg 45), suggesting this region of the small molecule makes
key contacts with IKKβ. Furthermore, a bromo- group at the R2 position of 13-197 was
also key for the molecule’s activity again suggesting this group was key for proper binding
to the target protein. These observations are being tested by Jacob Contreras who is
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developing 13-197 analogs with modifications at the R1 positions of the small molecule.
Testing of these analogs will yield further insight into the interactions made by these
groups.
In the SAR studies conducted with 25-4 (Figures 6.1 and 6.2 pgs 58 and 59),
reduction of the Michael acceptor resulted in loss of activity of the small molecule,
indicating loss of activity against NF-κB pathway members. This observation is consistent
with those for the reduction of the Michael acceptor of the natural product parthenolide.
Upon reduction of its Michael acceptor, parthenolide loses its activity towards IKKβ.122
Furthermore, these studies demonstrated that rigidification of the Michael acceptor was
key for 25-4 activity. This phenomenon suggests to us that rigidification of the small
molecule likely reduces interactions with off-target proteins by decreasing the flexibility of
the Michael acceptor and thus non-specific interactions with surface exposed cysteine
residues. This study can be expanded through generation and testing of additional
analogs that further explore the requirement for the Michael acceptor and its rigidification.
In luciferase screens with these small molecules, the known IKKβ inhibitor
parthenolide was used as a positive control. In studies with 13-197, parthenolide was
chosen as a control simply to demonstrate inhibition of NF-κB pathway activation by a
known IKKβ inhibitor.
Parthenolide’s use in the screen with 25-4 was two-fold. In this screen, it was again
used a positive control but it was also chosen because it shares the -methylene-butyrolactone present in 25-4. Parthenolide’s use in this screen thus gave us information
regarding the level of pathway inhibition that could possibly be expected upon treatment
with 25-4 and its analogs. Furthermore, the use of reduced-parthenolide allowed us to
demonstrate the requirement of the Michael acceptor for parthenolide’s activity in the
screen and to establish a rationale for 25-18’s (reduced 25-4’s) lack of activity. 25-4
showed inhibition of NF-κB pathway activity that was comparable to inhibition by
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parthenolide (75% vs 100%) (Figure 6.2 pg 59). Additionally, the IC50 value for
parthenolide in our TNF-induced IKKβ-mediated NF-κB-driven transcription assay is
4.7±1.5 µM,127 which was in line with the IC50 value of 25-4 in this cell line.
Parthenolide showed approximately 55% inhibition of TNF-induced, IKKβmediated, NF-κB-driven transcription in the screens conducted with 13-197 (Figure 5.3 pg
45) while it showed nearly complete inhibition of NF-κB activity in screens with 25-4 and
its analogs (Figure 6.2 pg 59). The parthenolide used in the studies with 25-4 was made
fresh and specifically for testing alongside 25-4. Whenever I conducted the assays with
13-197, the parthenolide stock solution used was not made fresh but had instead been
made by Dr. Vashti C. Bryant during her studies. Issues regarding the stability of this
natural product in DMSO or over the course of many freeze-thaw cycles could have
contributed to this discrepancy.
Target Validation: 13-197
The next experiments performed with 13-197 and 25-4 were directed at
determining the molecular targets of the small molecules. For 13-197, the small molecule’s
activity towards a panel of kinases was determined in kinase assays carried out by
Reaction Biology Corp. (Figure 5.4 pg 46). An initial screen was conducted in which 13197 was tested at 1 µM against a panel of kinases. The resulting hits from these single
concentration assays were then incubated with 13-197 at 10 concentrations starting at
100 µM compound with 9 1:3 serial dilutions to generate IC50 values. Six kinases were
identified as hits of 13-197 in the screen. These included TRKA, IKKβ, EPHA6, Nek3,
MAP4K4 and STK25. The IC50s for TRKA, IKKβ, EPHA6 and Nek3 were in the low µM
range while those for MAP4K4 and STK25 were in the mid µM range. Due to their lower
IC50 values, we focused our attention on the kinases TRKA, IKKβ, EPHA6 and Nek3.
MAP4K4, however, is known to be activated by TNF.155 TRKA plays a role in the
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development and maturation of the central and peripheral nervous systems.156 EPHA6 is
expressed mainly in the brain.157 Nek3 plays a role in the motility of breast cancer cells.158
Due to the physiological roles of these kinases, we chose to move forward by
characterizing the effects of 13-197 on IKKβ as it is the main kinase in the NF-κB pathway.
Nevertheless, we are mindful of the fact that inhibition of Nek3 and MAP4K4 may also
play a role in the phenotypes induced by 13-197 treatment.
The human kinome contains 518 kinases159 while the panel used in the Reaction
Biology Corp. screen only contained 318 kinases. Though the implications of this study
are limited by the size of the panel used, the results establish 13-197 as an inhibitor of
IKKβ and confirm that inhibition of NF-κB-driven transcription by 13-197 in the luciferase
assay was indeed likely due to targeting of the NF-κB pathway. To further confirm inhibition
of IKKβ by 13-197, Dr. Vashti C. Bryant, performed and in vitro ELISA assay with IKKβ
and 13-197. In this assay, 13-197 inhibited IKKβ with an IC50 of approximately 14 µM,
again confirming these results. These experiments are in line with experiments confirming
inhibition of IKKβ by the commercially available IKKβ inhibitors TPCA-1118 and BMS345541119 though our kinase screen was much more expansive (318 kinases vs 10 and
15 kinases, respectively). Though off-target effects through inhibition of TRKA, EPHA6
and Nek3 have not yet been assessed, we expect those through inhibition of MAP4K4
and STK25 to be minimized by the use of sub-IC50 concentrations of 13-197 for these
proteins. Through SAR studies we may be able to identify analogs of 13-197 that have
increased specificity for IKKβ. The use of these small molecules, other known IKKβ
inhibitors and RNA silencing of IKKβ alongside 13-197 in phenotypic assays (cell
proliferation, death, angiogenesis) in which 13-197 is expected to display activity may give
insight into off-target effects of 13-197 that could be mediated by inhibition of these
proteins.
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Target Validation: 25-4
As the -methylene--butyrolactone in 25-4 is also present in parthenolide, which
has been shown to target C179 of IKKβ and C38 of NF-κB subunit p65122, 130 we first sought
to validate binding of 25-4 to these targets. To do this, we used click chemistry (Figure
6.3A pg 60), which is emerging as a powerful strategy for identifying the targets of covalent
small molecules.148, 160 For these experiments, an alkyne-tagged version of 25-4 (31-036)
was synthesized by Dr. Sandeep Rana in the lab. Following incubation with live cells, cell
lysates or pure protein the alkyne tag on this small molecule, which is now covalently
bound to target, reacts with the azide tag of TAMRA-azide following incubation with TCEP,
TBTA and CuSO4×5H20 to generate a triazole product covalently linked to 31-036-targeted
proteins. Tagged protein is then precipitated with methanol to remove excess, unbound
TAMRA-azide and precipitated protein is resuspended in sample buffer, boiled and
resolved on SDS-PAGE. Importantly, the intrinsic fluorescent properties of the flurophore
allows for the visualization of targets via in-gel fluorescence. Click chemistry with 25-4
analog 31-036 confirmed binding of the small molecule to both IKKβ and p65. As these
results were in line with the activity of 25-4 in the luciferase assay, which reports
specifically on the inhibition of NF-κB pathway members, we moved forward to further
validate 25-4 as an inhibitor of IKKβ.
The pure p65 used for this experiment had a 14 amino acid truncation at the Cterminus, partially explaining its molecular weight of less than 65 kDa (Figure 6.3A pg 60).
In our experiments, this commercially available p65 consistently runs at the shown
molecular weight and reacts with anti-p65 antibody if the gel is transferred to a membrane
and blotted for p65 following visualization of in-gel fluorescence (data not shown). For this
experiment, we were unfortunately unable to generate a loading control. Following
detection of in-gel fluorescence, the gel was stained with Bio-safe Coomassie.
Unfortunately, the amount of protein loaded on the gel appears to be below the limit of
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detection for the reagent. In subsequent experiments, equal loading may be confirmed by
silver staining.
Though binding to IKKβ and NF-κB specifically was assessed in this experiment
(Figure 6.3A pg 60), 25-4 and 31-036 are covalent small molecules that react with surface
exposed cysteine residues in cells. Due to this mechanism of action, these small
molecules likely bind targets besides IKKβ and p65. However, the point of this experiment
was only to validate that 25-4 has targets within the NF-κB pathway that overlap with
parthenolide’s targets as 25-4 contains the same Michael acceptor present in the NF-κB
pathway inhibitor parthenolide and exhibited activity against NF-κB pathway activation in
the luciferase screen.
Distinguishing IKKβ/NF-κB-dependent effects from IKKβ/NF-κB-independent effects: 13197
Given that 13-197 has been shown to target kinases besides IKKβ (TRKA, EPHA6,
Nek3, MAP4K4 and STK25), future studies will be aimed at determining the consequences
of targeting these proteins alone and in combination with IKKβ. Experiments with siRNA
and small molecule inhibitors will be conducted to determine how loss of these proteins'
activities and loss of IKKβ activity affect cellular function. For example, MiaPaCa-2 cells
will be transfected with siRNA against each individual target to assess the consequence
of inhibiting each individual target to provide insight into IKKβ-dependent and possible
IKKβ-independent effects of 13-197. Additionally, siRNA against all 6 targets and siRNA
against the 5 non-IKKβ targets will be pooled to compare the effects of silencing all targets
of 13-197 and all non-IKKβ targets of 13-197. Furthermore, treatment with 13-197 will be
compared to treatment with the pool of siRNA against all 6 of the small molecule's known
targets and the 5 non-IKKβ targets of 13-197. If inhibition of IKKβ by 13-197 is indeed key
for the small molecule's anticancer activity, transfection with the pooled siRNA of nonIKKβ targets will not yield the anticancer effects associated with 13-197 treatment
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(decreased cell viability, reduced levels of anti-apoptotic proteins). However transfection
with siRNA against IKKβ alone or the pool of all 6 siRNAs including anti-IKKβ siRNA will
recapitulate treatment with 13-197 if IKKβ inhibition is key for the molecule's activity.
Furthermore, addition of an IKKβ inhibitor such as ML120B or TPCA-1 to cells transfected
with the pool of non-IKKβ siRNAs should mimic all IKKβ-dependent effects of 13-197
treatment. Additionally, treatment with 13-197, ML120B and TPCA-1 will be compared to
treatment with siRNA against IKKβ alone to validate that treatment with the small
molecules replicates silencing of IKKβ. If the effects of 13-197 do not appear to be due
solely to inhibition of IKKβ by 13-197 (for example, if treatment with 13-197 does not mimic
treatment with IKKβ siRNA alone but more closely mimics treatment with the pool of siRNA
against all 6 targets), siRNA against IKKβ will be tested in MiaPaCa-2 cells in combination
with siRNA against the other targets one by one to test for sensitization to treatment with
IKKβ siRNA. This may answer questions regarding the importance of targeting other
pathway members upstream of IKKβ (MAP4K4) or those with known roles in cancer
progression (Nek3).
Distinguishing IKKβ/NF-κB-dependent effects from IKKβ/NF-κB-independent effects: 254
Given that most of the targets of 25-4 are still unknown, assessing the IKKβ/NFκB-dependent effects of 25-4 will be a challenging task. Experiments designed to identify
the targets of 25-4 are currently underway. Briefly, cells will be treated with 25-4 analog
31-036, harvested and lysed. Next click chemistry will be performed as previously
described with lysate and TAMRA-biotin-azide to covalently attach biotin to the 31-036
covalently linked to target proteins. Lysate will then be incubated with streptavidin beads
to pull down the targets of 31-036. Mass spectrometry will be performed to identify these
targets. A benefit of this methodology is that all proteins (enzymes, transcription factors,
etc.) targeted by 31-036 can be identified using a single technique.
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Once the targets of 25-4 analog 31-036 are known, studies assessing the
IKKβ/NF-κB-independent effects of 25-4 can be conducted. Analysis of the known
consequences of inhibiting 31-036 or 25-4 targets may provide insight into any IKKβ/NFκB-independent effects on viability and apoptosis. Furthermore, click chemistry SAR
studies with 31-036 analogs will be conducted to identify analogs with fewer targets.
Treatment of cells with analogs that all target IKKβ and p65 but distinct non-IKKβ and NFκB targets of 25-4 analog 31-036 may give information regarding other targets that are
essential for the anticancer properties of the parent compound 25-4. Once the targets of
31-036 are known and analogs targeting IKKβ, NF-κB and distinct subsets of 31-036’s
other targets have been identified, we may perform siRNA studies similar to those
proposed for 13-197 with 31-036 analogs with only a few (~5 or fewer) targets. In addition
to transfecting cells with each siRNA individually, we will also transfect cells with pooled
siRNA against all the known targets of an analog. In these studies, we will measure
decreased viability, induction of apoptosis, inhibition of IκB phosphorylation and p65
nuclear translocation (to monitor IKKβ/NF-κB pathway inactivation) and the downstream
consequences of inhibiting the non-IKKβ and NF-κB targets of the analogs. Comparison
of the degree of decreased viability and induction of apoptosis in cells treated with different
siRNAs against non-IKKβ and NF-κB targets may reveal that inhibition of other pathways
contributes to the decreased cell viability and induction of apoptosis seen by 25-4.
Lastly, the described studies using C179A IKKβ and/or C38S p65 expressing cells
will give further insight regarding the IKKβ and p65-independent effects of 25-4 (and 25-4
analogs). Cells expressing C179A IKKβ will be resistant to IKKβ inhibition by 25-4 while
C38S expressing cells will be resistant to inhibition of p65 DNA binding by 25-4. Cells
expressing both C179A IKKβ and C38S p65 will be resistant to inhibition of both IKKβ and
p65 by 25-4. Overall, use of the C179A or C38S cell lines will elucidate the importance of
targeting IKKβ or p65 while the use of cells expressing both C179A IKKβ and C38S p65
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will give insight into the IKKβ and NF-κB-independent effects of 25-4. For example, if 254 treatment of C179A IKKβ/C38S p65 expressing cells still results in decreased cell
viability or induction of apoptosis, we can conclude that 25-4's anticancer effects may be
partially due to inhibition of other targets. Identification of analogs that still target IKKβ and
p65 but exhibit no anticancer activities in C179A IKKβ/C38S p65 expressing cells may
identify analogs that are selective for the NF-κB pathway.
Though 25-4 has many targets and IKKβ and NF-κB-independent effects likely
contribute to the anticancer effects of the small molecule, 25-4 is a small molecule that
binds IKKβ and NF-κB, displays anticancer effects and is highly amenable to modification.
As such, we intend to use the small molecule as a scaffold onto which we can, through
functionalization, build specificity onto this molecule to design a more specific, yet still nontoxic, inhibitor of IKKβ and p65. The studies outlined in this dissertation provide preliminary
evidence that IKKβ can be targeted with small molecules without inducing toxicity but
future studies by our lab will be required to develop small molecule 25-4 as a specific
inhibitor of the NF-κB pathway.
Mechanism of action: 13-197
As our luciferase assay reports on TNF-induced IKKβ activation, we tested the
ability of 13-197 to inhibit the phosphorylation of IκB, the downstream target of IKKβ,
following cellular stimulation with TNF (Figure 5.5 pg 47). For this studies, cells were
pretreated with 13-197 for 2 hours prior to stimulation with TNF for increasing times. In
the first of these studies, HEK293 cells were pretreated with DMSO or 13-197 for 2 hours
and then stimulated with TNF for 0, 5, 10, 15, 20, 30, 45, 60, 75, 90 and 120 minutes
and levels of phosphorylated and total IκB were monitored. In this experiment, 13-197
did not markedly decrease phosphorylation of IKKβ’s substrate at early time points but
instead decreased phosphorylation of IκB following the degradation and resynthesis of
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IκB in response to signaling through the NF-κB pathway (this phenomenon of IκB
degradation and resynthesis is not unique to our studies but rather appears to be a general
feedback mechanism for regulating the activation of the pathway161). To us, this
experiment suggested that 13-197 was inhibiting a form of IKKβ that persists at later time
points but is not present immediately following activation of the kinase.
It is well-accepted that IKKβ is phosphorylated upon its T loop serine residues to
drive its activation. Once activated, the kinase autophosphorylates a stretch of its own Cterminal serine residues, which serves to dampen the kinase’s activity and provides
docking sites for phosphates that can dephosphorylate the T loop serine residues to return
the kinase to a resting state.2, 125 Using this model (Figure 3.6 pg 32) for the progressive
phosphorylation of IKKβ, we hypothesized that 13-197 selectively targets IKKβ with its T
loop phosphorylated but allows the activation of unphosphorylated IKKβ to yield brief
signaling through the pathway.
As ML120B pre-treatment had already been shown to inhibit the early activation of
IKKβ in response to stimulation with TNF,117 we decided to compare inhibition of TNFinduced IKKβ activation by 13-197 and the IKKβ inhibitor TPCA-1 (Figure 5.6 pg 48).
HEK293 cells were pretreated with DMSO, TPCA-1 or 13-197 and then stimulated with
TNF for 5 or 10 minutes. Like ML120B, pre-treatment with TPCA-1 completely blocked
phosphorylation of IκB upon cellular stimulation with TNF. 13-197, on the other hand,
allowed marked phosphorylation of IκB within 10 minutes of stimulation, again
suggesting the small molecule allows the activation of IKKβ.
Both of these studies analyzed downstream effects of the activation of IKKβ in
response to stimulation of the kinase with a known IKKβ activator and are nearly identical
to experiments establishing ML120B as an inhibitor of IKKβ and similar to experiments
establishing TPCA-1 as an IKKβ inhibitor.117, 118 However, these experiments have not

89
addressed the possibility that 13-197 targets a kinase upstream of IKKβ to block
phosphorylation of IκB or decreases the levels of IKKβ by inhibition of its transcription,
for example. Immunoblotting for phosphorylated (and thus activated) IKKβ and total IKKβ
alongside blotting for phosphorylated and total IκB would establish that IKKβ was indeed
activated (high IKKβ phosphorylation) and inhibited (low IκB phosphorylation). However,
these experiments were performed prior to our lab’s identification of suitable antibodies
for detecting total and phosphorylated IKKβ. In future repeats of these experiments,
lysates will also be probed for phosphorylated and total IKKβ.
Importantly, the mechanism of action established in these studies with 13-197 is
in contrast to what is seen with ML120B and TPCA-1, which have both shown toxicities in
animal models.74, 162 As partial or transient inhibition of IKKβ has been hypothesized to be
less toxic than complete inhibition of IKKβ,163 we continued our studies with this small
molecule by testing it for efficacy against cancer cell lines (continued in next section
discussing 13-197).
Mechanism of action: 25-4
As mentioned already, parthenolide covalently interacts with C179 of IKKβ and
C38 of p65.122, 130 We expect 25-4 to bind to these proteins through covalent interactions
with the same residues through the -methylene--butyrolactone present in its structure.
We have not tested this mechanism of action directly, though follow-up studies with 25-4
and its reduced analog 25-18 indicate that covalent interaction between the Michael
acceptor and exposed cysteine residues of an NF-κB pathway member are indeed key for
activity (Figures 6.1 and 6.2 pgs 58 and 59). Our first cell-based studies were used to
validate the SAR seen with the butyrolactone analogs in the luciferase assay. Due to NFκB’s known roles in disease progression, anti-apoptosis and chemoresistance in breast
cancer76-79 we opted to study the pathway in breast cancer cells as well as pancreatic
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cancer cells. Basal activation of the NF-κB pathway is known to be high in MDA-MB-231
cells78 and is confirmed by the high basal levels of phosphorylated IκB in the MDA-MB231 cells used in these studies (Figure 6.3B pg 60). The high expression of IKKβ in these
cells has been linked to sensitivity to the IKKβ inhibitor sulindac, which drives apoptosis
in MDA-MB-231 cells.78
Reduced phosphorylation of IκB was observed in MDA-MB-231 cells treated with
25-4 (Figure 6.3B pg 60), which is expected as 25-4 was active in the luciferase assay.
Furthermore, treatment with the reduced version of 25-4 (25-18) resulted in no inhibition
of IκB activity, which again aligns with our results from the luciferase assay. As reduction
of the -methylene--butyrolactone of parthenolide resulted in loss of binding to IKKβ122
and activity towards NF-κB-driven transcription in our luciferase assay, our observation
that the Michael acceptor of 25-4 is key for activity is substantiated by work conducted
with similar molecules.
Treatment with small molecule 28-090 (25-4 in which the Michael acceptor has
been made less rigid), resulted in partial decrease in IκB phosphorylation but the small
molecule was less active than 25-4 (Figure 6.3B pg 60), suggesting rigidification of the
Michael acceptor is key for activity towards IKKβ. This observation is further supported by
the activity of cyclic 28-097C towards phosphorylation of IκB but lack of activity by its
acyclic analog 28-097A. Once more, the results of this experiment are in line with the
results of the luciferase assay (Figure 6.1 pg 58). Additionally, the molecules tested for
inhibition of IκB phosphorylation were able to do so at concentrations similar to those
used in the luciferase assay, demonstrating that the small molecules inhibit IKKβ activity
in cells with the same rank potency they displayed in the previous assay designed to test
their activity against the NF-κB pathway.
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Again, we hypothesize that rigidification of the Michael acceptor decreases
promiscuity of the cyclic small molecules by decreasing the number of interactions the
Michael acceptor may make with surface-exposed cysteine residues. Due to their inherent
flexibility, the acyclic 28-090 and 28-097A are able to interact with additional cysteine
residues in cells, thereby decreasing their activity towards NF-κB pathway members and
thus decreasing their activity towards IKKβ and NF-κB and reduction of IκB
phosphorylation and NF-κB-driven transcription. To further explore the importance of the
Michael acceptor or rigidification of the Michael acceptor, additional analogs with
modifications similar to those seen between 25-4 and 25-18 (reduction of Michael
acceptor), 25-4 and 28-090 (loss of rigidity of Michael acceptor), and 28-097C and 28097A (loss of rigidity of Michael acceptor) could be synthesized to further confirm this
phenomenon.
To further test that 25-4 binds to C179 of IKKβ, cells expressing mutant C179A
IKKβ (which cannot covalently interact with the -methylene--butyrolactone122) could be
treated with 25-4. Treatment of these cells with 25-4 should have no effect on IκB
phosphorylation if inhibition of IκB phosphorylation in these cells is due to inhibition of
IKKβ through covalent interaction with C179. However, if 25-4 is affecting a different
residue, an upstream kinase or total levels of IKKβ, inhibition of IκB phosphorylation will
still be seen. Validation that C179A IKKβ still phosphorylates IκB will be performed.
Furthermore, experiments similar to those conducted with 13-197 (pre-treatment with
DMSO or compound followed by stimulation with TNF for increasing times) may be
conducted to test if 25-4 binds resting IKKβ or selectively targets a phosphorylated form
of IKKβ. Again, in these experiments, levels of phosphorylated and total IKKβ and
phosphorylated and total IκB will be assessed to monitor if the kinase is active at early
time points and inhibited at late time points. However, as 25-4 also targets p65, it is
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important to remember that resynthesis of IκB may not occur in cells pretreated with 254 as the protein’s re-expression is driven by NF-κB translocation to the nucleus and
induction of transcription. In such an event, the experiment will be modified such that
treatment with 25-4, which binds it targets within 5 minutes (see 5 minute incubation with
31-036 followed by click chemistry, Figure 6.10 pg 68), will occur after stimulation with
TNF to drive phosphorylation and activation of IKKβ.
To test if inhibiting IKKβ gives the same effect as inhibiting both IKKβ and p65,
cells expressing C38S p65 (which cannot covalently interact with a Michael acceptor but
can still bind κB sites in DNA130) could be treated with 25-4 alongside wild-type cells. In
this experiment, 25-4 will inhibit both IKKβ and p65 in wild-type cells but only IKKβ in C38S
p65 cells. Prior to conducting this experiment alongside wild-type cells, p65 binding to
DNA as well as levels of total and phosphorylated IKKβ and IκB will be monitored in
untreated, C38S p65 cells to ensure the pathway is functioning properly in the mutant
cells. Upon treatment, levels of total and phosphorylated IKKβ and IκB will be monitored
and compared to levels in untreated cells to probe for inhibition of IKKβ as assessed by
decreased IκB phosphorylation. Additionally, p65 binding to DNA or translocation to the
nucleus can be monitored to assess pathway inhibition. With C38S p65 cells, pretreatment with drug followed by TNF stimulation could be performed, as p65 should still
be functional in these cells and will still drive IκB re-expression to give a readout
(decreased IκB phosphorylation) for IKKβ inhibition.
Overall, despite the limitations of this experiment, this mechanism-based study
verified that 25-4 inhibited the phosphorylation of IKKβ’s substrate IκB in MDA-MB-231
cells and validated observations from the SAR conducted in luciferase-expressing A549
cells.
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Mechanism-based studies in cancer cells: 13-197
As previously mentioned, we next sought to test the ability of 13-197 to inhibit the
phosphorylation of IκB in cancer cells. As NF-κB pathway activation is implicated in
pancreatic cancer72, 73, 90 and IKKβ activation is implicated in the development of K-rasdriven pancreatic cancers72, 93 we chose to study activation of IKKβ and the consequences
of its inhibition in pancreatic cancer cells.
First, we tested a panel of cancer cell lines for phosphorylated IKKβ and found that
IKKβ was indeed activated in these cells (Figure 5.7 pg 49). Next, we tested the ability of
13-197 to inhibit IκB phosphorylation in pancreatic cancer cells (Figures 5.8 and 5.9A
pgs 49 and 50). Treatment with 13-197 decreased IκB phosphorylation in a panel of
pancreatic cancer cells lines (AsPC-1, Capan-2, Hs766T, MIAPaCa-2 and SUIT-2) and
reduced phosphorylation of IκB in MIAPaCa-2 pancreatic cancer cells in a dose- and
time-dependent manner. As NF-κB regulates a number of genes that play a role in the
proliferation of cancer cells and genetic ablation or pharmacological inhibition of IKKβ has
been shown to reduce cancer cell proliferation,66, 74 we next determined if inhibition of the
pathway would result in decreased viability of cells (Figure 5.9B and C pg 50). Indeed,
treatment with 13-197 decreased the viability of pancreatic cancer cells with low µM
potency. Furthermore, the IC50 of 13-197 in this panel of cancer cell lines is within the
same range of potency of other small molecule inhibitors of IKKβ.
To further study the effects of 13-197 on cell proliferation, a collaborator, Dr.
Prakash Radhakrishnan, analyzed the effects of 13-197 on the cell cycle and saw that
treatment with the small molecule induces apoptosis, blocks cell cycle progression and
reduces levels of PCNA.128 These effects are in line with those seen with other
pharmacological inhibitors of IKKβ.74, 164, 165 As Bcl-xL, Mcl-1, XIAP and survivin are under
the transcriptional control of NF-κB,21, 23-25 I treated MIAPaCa-2 cells with 13-197 and
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probed lysates for expression of these anti-apoptotic proteins (Figure 5.10 pg 51).
Treatment with the small molecule resulted in decreased levels of these proteins,
providing a biological rationale for the results of Dr. Radhakrishnan’s studies. Furthermore,
these results are in line with those seen in other models of pharmacological IKKβ inhibition
or NF-κB pathway inhibition with the IκB superrepressor.166-168
Mechanism-based studies in cancer cells: 25-4
As the activation of the NF-κB pathway is implicated in the progression of not just
pancreatic cancer but many others, including lung,74, 75 breast,58, 76-79 ovarian,
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and

cervical107, 110 cancers and has been shown to play a role in inflammation, transformation,
proliferation, angiogenesis, invasion, metastasis, chemoresistance and radioresistance,83
we expanded the cells lines in our studies with 25-4 to encompass a diverse panel of
cancer cell lines.
As mentioned previously, 25-4 showed activity against phosphorylation of IκB in
MDA-MD-231 breast cancer cells (Figure 6.3B pg 60). Additionally, 25-4 displayed doseand time-dependent activity in MIAPaCa-2 pancreatic cancer cells (Figure 6.3C pg 60),
which were established to have basal phosphorylation of IKKβ (Figure 5.7 pg 49) and
basal phosphorylation of IκB (Figures 5.9A and 6.3C pgs 50 and 60) suggesting that the
NF-κB pathway is active in these cells. Furthermore, the IC50 for 25-4, as measured by
cell viability assay, in these two cell lines was in the low µM range, which is again, in line
with the IC50s for the known IKKβ inhibitors TPCA-1 and Bayer Compound VIII (Chapter 6,
Table 1 pg 62). 25-18 was again inactive in these cell lines, supporting the argument that
reduction of the Michael acceptor abolishes the small molecule’s activity. Furthermore, the
reported IC50 values for parthenolide against acute myelogenous leukemia, lung, breast
and pancreatic cancer cell lines is typically within the 0.5 to 17.5 µM range,169-172 which is
again in line with the potency of 25-4 in our studies.
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As IKKβ and the NF-κB pathway are known to play a role in many tumorigenic
properties of cancer cells, we next assessed the ability of 25-4 to inhibit colony formation
(Figure 6.5A and B pg 63) and induce apoptosis in cancer cells (Figures 6.5C and 6.6 pgs
63 and 64). The colony formation assay was conducted as this assay monitors the
reproductive viability of cancer cells after treatment with drug.173 Overexpression of NFκB is associated with increased colony formation by cervical cancer cells while silencing
of the protein results in decreased colony formation.107 To test if inhibition of IKKβ by 254 could prevent colony formation of cervical cancer cells, Tian Zhou performed colony
formation assays in HeLa cells treated with DMSO, 25-4 and the reduced version of 25-4
(25-18). In the assay, cells were seeded at low density (500-1000 cells/well) in 6-well
plates, given 24 hours to attach to the plate and treated with drug for 48 hours. The media
above the cells was replaced and the cells were cultured for 7 additional days before
fixation with methanol, staining and quantification of colonies. This method is similar to
that used by others104,

107, 174

to assess clonogenecity of cells with NF-κB activation.

Treatment with 25-4 dose-dependently inhibited colony formation while treatment with a
dose of 25-18 equivalent to the highest dose of 25-4 had no activity.
For this study, additional IKKβ inhibitors such as parthenolide, ML120B, TPCA-1
or Bayer Compound VIII could have been tested to show similar effects by known IKKβ
inhibitors. Furthermore, knockdown of IKKβ or p65 could also validate these results by
showing effects similar to those of 25-4 treatment. Additionally, cells overexpressing IKKβ
and p65 or cells expressing C179A IKKβ and C38S p65 could have been treated alongside
wild-type cells to show resistance to treatment or rescue of the phenotype by cells that are
expected to be resistant to 25-4 inhibition of IKKβ and p65.
NF-κB activation and IKKβ expression are associated with poor survival of ovarian
cancer patients and chemoresistance of ovarian cancer cells.80, 81, 99 As inhibition of IKKβ
has been shown to decrease viability of ovarian cancer cells99 and NF-κB pathway
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inhibition has been associated with increased ovarian cancer cell sensitivity to the
chemotherapeutic cisplatin,110 which is commonly used in the treatment of ovarian
cancer,150 we next tested the ability of 25-4 to decrease cell viability in A2780 and A2780
cisplatin-resistant cells. Treatment with the small molecule indeed decreased cell viability
of both cell lines (Chapter 6, Table 1 pg 62.). Again, the IC50 values for the cells were in
the low µM range. Furthermore, the IC50 values for cisplatin in these lines were in the low
µM range for A2780 cells while A2780 cisplatin-resistant cells were not sensitive to 20 µM
cisplatin (data not shown). These studies illustrate the usefulness of 25-4 in the treatment
of refractory disease. As most women who are treated for ovarian cancer will also face
recurrent disease,97 on-going experiments are testing the ability of 25-4 to resensitize
A2780 cisplatin-resistant cells to treatment with cisplatin to further assess the small
molecule’s usefulness in the treatment of refractory disease.
To explore the mechanisms behind the decreased viability seen in ovarian cancer
cells treated with 25-4 and to determine if the small molecule would sensitize cells to
treatment with cisplatin, SKOV3 ovarian cancer cells were treated with cisplatin, 25-4 or
the combination and caspase 3/7 activity was monitored as activation of caspases is a
hallmark of induction of apoptosis (Figure 6.5C pg 63).175 Treatment with 25-4 induced low
levels of caspase 3/7 activation while induction of caspase activity was also low following
treatment with cisplatin. When the two compounds were used in combination, marked
induction of caspase 3/7 activity was observed, suggesting that 25-4 sensitizes SKOV3
cells to treatment with cisplatin. In this study, doses of 25-4 and cisplatin than drive very
little induction of caspase 3/7 activation (5 µM) at the given time point (24 h) were chosen
for two reasons. We reasoned that combination with 2 very lose doses of drug will result
in fewer off-target effects and would induce the least toxicity in vivo. Thus, selecting
concentrations of drug that are not high enough to induce activation alone but give
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induction together were chosen to reduce off-target effects and to reflect dosages we think
would be most appropriate for in vivo use.
No combination index was calculated for this study with SKOV3 cells because a
dose-response curve for caspase 3/7 activation by 25-4 alone and cisplatin alone was not
calculated, which would be required to calculate a combination index.147 In this
experiment, caspase 3/7 activation by 24 hour treatment with 5 µM drug (25-4 alone,
cisplatin alone or 5 µM of each drug) only was assessed. Future studies assessing
caspase 3/7 activation by the compounds can be conducted in a dose-response format
so these values can be measured to calculate combination index values. Again, the same
methods mentioned for rescuing the phenotype of 25-4-treated cells in previous
phenotypic screens could be used to establish that inhibition of IKKβ is the primary
mechanism driving decreased cell proliferation and induction of caspase 3/7 activity.
PARP is an enzyme that functions to repair DNA following cellular stress.176 The
enzyme is the target of many proteases, including caspases, and its cleavage results in
the production of PARP fragments that mediate diverse forms of cellular death.176 As
inhibition of the NF-κB pathway induces apoptosis through inhibition of transcription of
anti-apoptotic proteins21, 23-25 and PARP cleavage is a hallmark of induction of apoptosis,177
we treated various cancer cell lines with 25-4 to see if the proposed IKKβ inhibitor could
induce PARP cleavage in cancer cells (Figure 6.6 pg 64).
MIAPaCa-2 and SKOV3 cells were treated with the indicated concentrations of 254 and 25-18 and etoposide for 24 h. In 24 h, 25-4 induced PARP cleavage in MIAPaCa-2
and SKOV3 cells and 25-18 was again inactive. Etoposide was used as a positive control
in both of these experiments but does not show induction of PARP cleavage. MIAPaCa-2
and SKOV3 cell lines were both particularly sensitive to induction of PARP cleavage upon
treatment with 25-4. Thus optimizing the treatment concentration and length of 25-4
exposure to induce PARP cleavage without inducing total cell death in these cell lines was
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quite difficult. After performing initial dose-response experiments at the 48 hour time point
(a time point when etoposide was expected to be active) and time-course experiments
with multiple concentrations, the best concentration and drug exposure time for MIAPaCa2 and SKOV3 cells appeared to be 24 hour treatment with 10 µM 25-4. As such, I opted
to treat MIAPaCa-2 and SKOV3 cells with etoposide for only 24 hours instead of treating
with etoposide for 48 hours starting 1 day after cell plating and treating with 25-4 for 24
hours starting 2 days after plating so an equivalent number of cells seeded on the same
day would be treated with each drug. These experiments were carried out at the same
time as those conducted with HeLa (48 hour treatment) and A2780 cells (96 hour
treatment) and the same etoposide was used in these experiments and was indeed active
48 and 96 hours following treatment.
The range of treatment times required for induction of PARP cleavage in these cell
lines is not surprising and has been noted with other small molecules. For example,
staurosporine, a non-specific kinase inhibitor that inhibits IKKβ,178 has been shown to
induce PARP cleavage in a matter of hours in some cells while induction of PARP
cleavage takes at least a day in others.179 As such, the various time points required to
induce PARP cleavage with 25-4 does not seem to be a phenomenon singular to these
experiments. However, the lack of PARP cleavage by etoposide at the 24 hour time point
in MIAPaCa-2 and SKOV3 cells is unlikely due to insensitivity to the drug. I suspect the
lack of activity is due instead to the short time point for which cells were treated. As
etoposide’s mechanism of action involves induction of DNA damage,180 at least one round
of cell division would have needed to occur for etoposide to induce activation of PARP
cleavage. Other small molecules that are known to inhibit signaling through the NF-κB
pathway have to been shown to induce cleavage of caspases,181 which is required for their
activation,182 within 4 hours of treatment. Such inhibitors or staurosporine may serve as
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more appropriate controls in future experiments as they may induce their effects through
the same pathway and at a relatively similar time point.
Interestingly, a decrease in total PARP but no cleaved PARP fragment was seen
in MIAPaCa-2, SKOV3 and A2780 cells treated with 25-4. This is again likely due again
to the difficulties associated with optimizing the concentration and length of 25-4
treatment. Time course experiments analyzing the activation of caspase 3 and caspase
7, which are known to cleave PARP,177 in these cells lines may yield a better idea of the
time points and appropriate treatment concentrations so these experiments may be
repeated to produce results more typical of a PARP cleavage assay (namely, presence of
total PARP and production of a PARP cleavage fragment by 25-4 and a positive control
that is known to induce DNA damage).
The difficulties associated with obtaining ideal results for this experiment are likely
due to the nature of the experiment. The positive and negative controls chosen for this
experiment (etoposide and 25-18, respectively) were indeed proper controls for showing
induction of PARP cleavage and no effect on PARP cleavage (Figure 6.6 pg 64, A2780
and HeLa lines). However, due to the differential sensitivity of some cell lines to treatment
with 25-4, some lines were not incubated with etoposide for a period of time sufficient to
see induction of PARP cleavage by the small molecule (Figure 6.6 pg 64, MIAPaCa-2,
SKOV3). Furthermore, treatment with 25-4 showed reduction of full-length PARP levels in
all cell lines though a cleaved PARP fragment was not seen in all cell lines. This is likely
due to the difficulty of selecting a treatment time at which the 89 kDa cleavage fragment
is present in cells at a level detectable by immunoblotting. Future work may refine the
timing issues associated with the studies by using a positive control that induces PARP
cleavage as rapidly as 25-4. Furthermore, harvesting cells at different time points may
yield 25-4-treated lysates with both full-length and the 89 kDa PARP fragment.
Furthermore, other cleavage fragments of PARP are known to be generated by enzymes
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other than caspases 3 and 7 including calpains and cathepsins, which can drive caspaseindependent apoptosis.176 In future experiments, immunoblotting for these fragments can
be performed to further study the cell death induced in cell lines by 25-4 treatment.
Animal-based studies: 13-197
To assess the ability of 13-197 to decrease tumor growth in a mouse model of
pancreatic cancer, MIAPaCa-2 cells were orthotopically implanted into the flanks of nude
mice, the mice were given two weeks to heal and were treated for 30 days with either
vehicle control or 13-197. At the end of this study, tumor weights and volumes were
analyzed as was metastasis (as measured by number of tumor nodules in other organs)
and proliferation (Figure 5.11 pg 53). Treatment resulted in a decrease in all of these
parameters.128 Though treatment with the IKKβ inhibitor TPCA-1 is associated with
toxicity, mouse studies with the small molecule have shown reduced proliferation of lung
cancer cells (as measured by Ki-67 staining), decreased PCNA staining and slower tumor
growth,74 all of which mirror our observations in 13-197-treated mice and provide further
proof that the effects of 13-197 are through inhibition of IKKβ. Furthermore, several groups
have reported decreased tumor formation following inhibition of NF-κB activity by deletion
of p65183 or by overexpression of the IκB superrepressor (nonphosphorylable IκB),184
suggesting again that the effects of 13-197 mirror inhibition of IKKβ.
The novel result of this experiment was the lack of toxicity seen with 30-day
administration of 13-197,128 as ML120B and TPCA-1, for example, have proven toxic in
previous studies. The lack of toxicity of the small molecule is likely due to the transient
activation of IKKβ that was seen after stimulation of HEK293 cells with TNF despite pretreatment with 13-197. These studies offer initial validation of the theory that partially
targeting IKKβ is a viable strategy for treating disease without inducing severe toxicity.163
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Future studies in our lab will be focused on purifying endogenous IKKβ from cells
stimulated with TNF for various times. Kinase assays with 13-197, purified IKKβ and
IκB will be performed to further validate that 13-197 selectively inhibits a phosphorylated
form of IKKβ to yield the pattern of inhibition of IκB phosphorylation seen upon pretreatment with 13-197 and stimulation with TNF. This will provide further proof that 13197 escapes the toxicities associated with previously published IKKβ inhibitors by allowing
early activation of IKKβ upon induction with TNF.
Animal-based studies: 25-4
To continue investigating the anticancer properties of 25-4, our collaborators at
Josephine Ford Cancer Center (Henry Ford Hospital) tested the small molecule in an
orthotopic model of ovarian cancer. Two studies were conducted. In the first, a small dose
escalation study with 25-4 was performed. Nude mice were injected with 2 million A2780
cells and after 3 days mice were divided into 25-4-treated, cisplatin-treated or untreated
groups. The small molecule 25-4 was dosed at 1, 2.5 or 5 mg/kg 25-4 daily for 4 weeks
while cisplatin was dosed at 2 or 4 mg/kg on days 5, 9, 14 and 21. This dosing regimen
for 25-4 was chosen as it was expected to produce detectable levels of 25-4 in plasma
and that for cisplatin was chosen to avoid toxicity in the mice. Mice were then sacrificed
and tumor weights were analyzed (Figure 6.7 pg 65). Treatment with 1 mg/kg cisplatin
resulted in ~15% reduction in tumor weights while treatment with 2.5 mg/kg resulted in
~20% reduction of tumor weights and 5 mg/kg treatment resulted in ~45% reduction in
tumor weights. However, toxicity (blocked bowels) was noted at the highest dosage of the
drug. Treatment with 2 mg/kg cisplatin resulted in ~25% reduction of tumor weights and
treatment with 4 mg/kg resulted in ~75% reduction in tumor weights. Toxicity (blocked
bowels) was also noted at the highest concentration of cisplatin. As NF-κB pathway
inhibition has been shown to sensitize cancer cells to cisplatin110 and 25-4 sensitized
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ovarian cancer cells to treatment with the drug in cell-based studies conducted in the lab,
a follow-up study to assess the ability of 25-4 to sensitize A2780 cells in mice to cisplatin
was performed. Following the same outline of the studies presented above, mice were
treated with 2.5 mg/kg 25-4 and 2 mg/kg cisplatin in combination as these concentrations
did not induce overt toxicity in mice but did reduce tumor weights. Treatment with the two
in combination resulted in nearly ~70% reduction of tumor weight compared to
approximately 20% (25-4) and 25% (cisplatin) reduction of tumor weights alone.
Immunohistochemistry studies were performed on ovarian tissues extracted from
the mice following treatment (Figure 6.8 pg 66). Levels of Mcl-1 were analyzed in these
tissues. Again, Mcl-1 is a known target gene of NF-κB and its upregulation likely plays a
role in chemoresistance.185, 186 In mice treated with 25-4, Mcl-1 staining was reduced by
approximately 66%. Treatment with cisplatin again resulted in a decrease similar to that
seen with treatment with 25-4. The combination had a similar effect.
Resistance to cisplatin has been associated with increased phosphorylation of
IκB and NF-κB activity in cisplatin-resistant A2780 cells and cisplatin treatment has been
shown to be less effective at reducing IκB phosphorylation and NF-κB activity in cisplatinresistant cells.82 Furthermore, treatment of ovarian cancer cells, including A2780 cells,
with cisplatin has even been shown to activate IκB degradation in cells.187 This activation
of the NF-κB pathway is hypothesized to be a mechanism by which cisplatin resistance
develops and the up-regulation of anti-apoptotic proteins by NF-κB is likely key for the
development of this resistance.188 As such, we expected treatment of A2780 tumorbearing mice with cisplatin and 25-4 to lead to a synergistic decrease in tumor size as we
hypothesized that treatment with 25-4 would counter any NF-κB pathway activation by
cisplatin or rescue any lost NF-κB inhibitory activity of cisplatin in any A2780 cells that had
developed resistance during the course of the study. As decreased levels of Mcl-1 (an
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anti-apoptotic protein under transcriptional regulation of NF-κB) were seen in our cisplatintreated mice and these levels were comparable to those seen in 25-4 treated mice, we
concluded that our cisplatin-treated mice did not develop resistance to cisplatin and thus
we did not observe the synergism in 25-4 and cisplatin-treated mice we hypothesized we
would see. Given the downregulation of Mcl-1, and not upregulation of Mcl-1, by cisplatin,
there was little potential for synergistic decrease of the protein’s levels in this study. That
is to say, for these two small molecules that each reduced Mcl-1 staining by 66% to have
shown synergistic decrease in Mcl-1 levels at these dosages, more than 100% reduction
in the levels of Mcl-1 would have been required.
Future studies could focus on testing the combination of 25-4 and cisplatin in
A2780 cisplatin-resistant cells, which in our hands have shown 25-4 sensitivity similar to
A2780 cells (IC50 = ~3 µM for A2780 cisplatin-resistant cells and ~2.3 µM for A2780 cells)
but are insensitive to cisplatin at 5X the drug’s IC50 for A2780 cells (A2780 cisplatinresistant cells are insensitive at 20 µM while A2780 cells have an IC50 of ~4 µM) (data not
shown). However, the cisplatin-resistant cells used in our studies do not form tumors in
mice and were thus unable to be tested in the mouse model outlined above. Furthermore,
a study in which mice with A2780 tumors are treated with low doses of cisplatin to induce
resistance and then treated with 25-4 in combination with cisplatin to test if 25-4 treatment
can resensitize ovarian cancer cells to cisplatin could be designed. It would be interesting
to see if cisplatin-resistant A2780 tumors display increased levels of phosphorylated IκB,
nuclear p65 and Mcl-1 during the development of resistance, suggesting that NF-κB
activation does indeed drive chemoresistance.
The novelty of these studies was again the lack of toxicity noted with a therapeutic
dose of 25-4 (2.5 mg/kg). Previous studies testing the inhibition of the NF-κB pathway in
ovarian cancer have shown decreased tumor weights in mice.189 Furthermore, NF-κB
pathway inhibition by curcumin, an IKKβ inhibitor, has been shown to induce apoptosis in
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ovarian cancer cells,190 which could be driven by reduced levels of the anti-apoptotic
protein Mcl-1,185, 186 thus the activity of 25-4 in these models is aligned with the known
consequences of inhibiting the NF-κB pathway in ovarian cancer cells. Again, treatment
with cisplatin is known to induce NF-κB pathway activation in A2780 cells so the
downregulation of Mcl-1 in cisplatin-treated cells and consequent lack of sensitization to
cisplatin by 25-4 was unexpected.
To ensure that the effects of 25-4 in this study were due to the inhibition of the NFκB pathway through inhibition of IKKβ and p65, two of its known targets, these studies
could be expanded. More slides can be generated from our tumor microarray and
analyzed for additional tumor properties that are known to be regulated by the NF-κB
pathway such as proliferation (staining of Ki-67 or PCNA) and angiogenesis (CD31
staining).190 Furthermore, as the NF-κB pathway is known to regulate the expression of
cyclins,191 staining for cyclins could be performed. Importantly, tissue staining of
phosphorylated and total IKKβ, IκB and p65 could be done to ensure the IKKβ was
activated (high phospho-IKKβ staining) but inhibited (low phospho-IκB, phospho-p65
staining) in tumor tissues.
Upon sacrifice, gastrointestinal complications (likely constipation or impaction)
were noted in mice treated with the highest dosages of 25-4 and cisplatin. Constipation is
the slow movement of feces through the large intestine, while impaction is the build up of
hardened feces in the colon. Constipation is commonly caused by the intake of too little
water while impaction may also be associated with both cardiac and respiratory
symptoms.192 Unfortunately, the mice in the study were not being monitored for water
intake or cardiac or respiratory symptoms and these symptoms were not obvious to
researchers conducting the study, so it is difficult to determine the specific reason for the
observed blockages. These gastrointestinal complications, however, are among the most
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common side-effects of treatment with chemotherapeutics192 and can usually be alleviated
if brought to the attention of a physician.
Lack of toxicity: 13-197
Our HEK293 cell-based studies that suggest 13-197 targets a later-acting,
phosphorylated form of IKKβ while allowing early activation of IKKβ (Figure 5.5 pg 47)
served as our first clue that the small molecule may not exhibit the toxicities associated
with other inhibitors of the kinase. The most recently solved crystal structure of human
IKKβ has given us further insight in the mechanism of action of 13-197, though future
studies with the small molecule and protein will be required to validate these hypothesizes.
Shenping Liu et al. obtained the crystal structure of a dimer of human IKKβ in
complex with the ATP competitive inhibitor K252a. In this structure, one IKKβ protomer
was phosphorylated while the other was not (Figure 3.2 pg 26). Analysis of the activation
loop of phosphorylated and unphosphorylated IKKβ suggests that upon phosphorylation
of the T loop serine residues, the activation loop of phosphorylated IKKβ moves by
approximately 21Å and the conformational changes induced upon phosphorylation results
in IKKβ protomers with distinct conformations. Though the ATP binding sites are nearly
identical in either state, the conformational changes that occur upon phosphorylation could
allow for the design of non-ATP competitive inhibitors of IKKβ that discriminate between
active and inactive kinase. For example, phosphorylation of the IKKβ T loop serine
residues creates a binding site for its substrate IκB. Binding to this site in the active
kinase is hypothesized to inhibit only the activated form of the kinase.47
As our studies suggested that 13-197 preferentially targets phosphorylated IKKβ
over nonphosphorylated IKKβ, which have nearly identical ATP binding sites, we
outsourced kinase assays to Reaction Biology Corp. to test if 13-197 is a non-ATP
competitive inhibitor. If the small molecule is preferentially targeting activated IKKβ, it
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should be binding somewhere besides the ATP binding site. The results from these assays
indicate that 13-197 is indeed a non-ATP competitive inhibitor (data not shown).
The substrate binding site is one of the main sites that undergoes a conformational
change upon phosphorylation of the kinase. To test that 13-197 competes with substrate
binding of phosphorylated IKKβ, a binding assay may be performed with active IKKβ, 13197 and IκB. Immunoprecipitation of activated IKKβ followed by immunoblotting for IκB
could be performed (and vice versa) after incubating the two proteins in the presence of
increasing concentations of 13-197. If 13-197 treatment decreases binding of IκB to
IKKβ, reduced levels of IκB would be co-immunoprecipicated with IKKβ with increasing
concentrations of 13-197. To perform these studies, phosphorylated and active IKKβ (or
constitutively active S177/181E IKKβ) would be incubated with a nonhydrolyzable ATP as
ATP binding is a prerequisite for substrate binding to enzyme193 followed by incubation
with 13-197 and IκB and immunoprecipitation. The use of activated IKKβ and
nonhydrolyzable ATP would allow binding of both 13-197 and IκB to the site of interest
in active IKKβ. Crystalization of 13-197 in complex with active IKKβ would, however, best
elucidate how the small molecule binds the kinase.
Lack of toxicity: 25-4
Studies with the natural product parthenolide, which features the same methylene--butyrolactone that is present in IKKβ, binds to C179 of IKKβ and C38 of
p65.122, 130 Studies with IKKβ and p65 mutants have shown that conversion of C179 of
IKKβ to alanine and conversion of C38 to serine in p65 results in loss of inhibition by the
small molecule as alanine and serine residues cannot react with the Michael acceptor of
the natural product.122, 130 Using these same IKKβ and NF-κB mutants, we could confirm
that binding to the proteins is through these same residues.
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The newly solved crystal structure of human IKKβ with a phosphorylated and
unphosphorylated protomer also gives insight into 25-4’s mechanism of action. In
phosphorylated IKKβ, C179 (which is the target of parthenolide and the presumed target
of 25-4) is solvent exposed. However, in unphosphorylated IKKβ, the T loop residues
seem to be in a conformation that would not facilitate binding of 25-4 to C179.
Unfortunately, critical residues of the activation loop were missing in the crystal structure
of unphosphorylated IKKβ, so how accurately this structure reflects the true structure of
unphosphorylated IKKβ is highly debatable. Moving forward, we will conduct work that
establishes a mechanism for the lack of toxicity of 25-4. Experiments similar to those
conducted with 13-197 and TNF-stimulated cells will be performed. HEK293 cells will be
pretreated with drug for 2 hours and then the cells will be stimulated with TNF for
increasing periods of time. If pre-treatment with 25-4 results in the inhibition of IKKβ
present at later time points after TNF stimulation, as was seen with 13-197, then 25-4
could indeed preferentially inhibit phosphorylated IKKβ and the theories generated by
review of this crystal structure could indeed be valid. Again, this experiment may need to
be modified such that cells are stimulated first and then treated with drug as 25-4 also
inhibits NF-κB function and may thus block the resynthesis of IκB and limit our abilities
to assess IKKβ function as 25-4 treatment may affect our mechanistic readout (without
IκB resynthesis we cannot monitor IκB phosphorylation at late time points) of its activity.
Furthermore, 25-4 IC50 values for inhibition of IκB phosphorylation by inactive and
activated IKKβ could be determined using IKKβ purified from cells at different time points
(prior to and after stimulation of TNF) or S177/181A and S177/181E IKKβ (inactive, T
loop nonphosphorylable and constitutively active, T loop phospho-mimic IKKβ,
respectively).
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Though these pre-treatment followed by stimulation with TNF studies can be
readily conducted in our laboratory, identification of targets by mass spectrometry will give
a much broader view into the off-target effects of the small molecule and a very focused
answer to which form of IKKβ is targeted by 25-4. Briefly, streptavidin pulldowns of
TAMRA-biotin-azide tagged 31-036-treated lysates will be performed to isolate proteins
targeted by 31-036. These protein targets will be analyzed by mass spectrometry to
determine binding partners of 31-036. Importantly, the structure of 25-4 is highly amenable
to modification with functional groups that will allow us to perform subsequent SAR studies
with 25-4 analogs. These studies will be aimed at identifying analogs that bind a single or
a small subset of the targets of 25-4, so we may study the effects of targeting each protein
that covalently interacts with the small molecule.
Interestingly, despite targeting both IKKβ and p65, 25-4, like parthenolide,
displayed little toxicity in mice. Even if the small molecule preferentially targets activated
IKKβ, it must also target an activated form of p65 to prevent total shutdown of the pathway.
It is possible that prior to its degradation, IκB’s interaction with p65 blocks 25-4 binding
to p65, possibly through alteration of the protein’s structure. Though 25-4 is expected to
bind to targets quickly (within 5 minutes), the time required for 25-4 to bind to p65 after
the protein’s release from IκB may be just long enough to allow a pool of p65 to
translocate to the nucleus and drive transcription necessary for survival of normal cells,
particularly T and B cell precursors as their death is associated with the inhibition of the
NF-κB pathway.162 However, this level of NF-κB transcription may not be sufficient for the
survival of cancer cells, providing a therapeutic window for the small molecule. Again,
partial inhibition of the pathway with small molecules is predicted to be less toxic than
complete and sustained inhibition of NF-κB pathway activity.163
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Click chemistry with 25-4 analog 31-036
We chose to pursue click chemistry followed by reaction with an azide- or biotinazide-tagged TAMRA so we could perform visualization of targets via fluorescence and
purification of targets via the high affinity interaction between biotin and streptavidin beads
or resins, as these are emerging as very powerful techniques for the visualization and
analysis of cellular targets of small molecules. Click chemistry reactions are particularly
attractive for a number of reasons: 1) they are fast, high-yielding and relatively easy to
optimize, 2) the azide and alkyne functional groups used in our reaction interact only with
one another under the conditions of click chemistry and 3) click-based methods are
compatible with the cellular environment allowing the reaction to occur in live cells.
However, in designing a click probe, certain considerations must be taken. For example,
the click probe must retain the binding properties of its parent small molecule (that is to
say, 31-036 must display the same activity as 25-4). Furthermore, the click probe needs
to retain cell permeability to be used in live cells.160 In the initial validation of 31-036 as a
viable click probe, we incubated the probe with live cells at a concentration comparable to
those used in studies with 25-4, washed away excess probe, harvested cells, performed
the click reaction with TAMRA-azide and used in-gel fluorescence to ensure that the probe
was indeed able to bind targets within live, intact cells (Figure 6.9 pg 67). We also
performed dose- and time-response studies with the small molecule to investigate what
concentration of the molecule was required to saturate our signal and how quickly the
small molecule could bind targets (Figure 6.10 pg 68). These studies gave us an idea of
the best concentration of the small molecule to use in follow-up studies and how short of
an incubation we could perform with the small molecule.
Furthermore, we performed a very rudimentary competition assay with 31-036 and
25-4 (Figure 6.11 pg 69) based upon the methodologies of Kwok et al.122 to demonstrate
that 25-4 and 31-036 bind similar targets in cells. In this experiment, cells were incubated
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with 31-036 for 1 hour, 25-4 for 1 hour, or 25-4 for 1 hour followed by 31-036 for 1 hour.
Cells were harvested, lysates were incubated with TAMRA-azide and resolved on SDSPAGE and in-gel fluorescence was visualized. These experiments show that when cells
are pre-treated with 25-4 prior to treatment with 31-036, the intensity of the 31-036 click
signature is diminished. This experiment is limited by the fact that I was unable to obtain
a loading control.
Additional experiments to outline binding of 31-036 to the same targets of 25-4 will
be conducted in the future. In these experiments, the same treatment strategy as above
will be performed (treatment with 31-036 only, treatment with 25-4 only, and treatment
with 25-4 followed by treatment with 31-036). However, a wide range of 25-4
concentrations will be used. In these studies, concentrations of 25-4 that are equivalent to
1/10X, 1X, and 10X 31-036 with intervening concentrations will be used to show doseresponsiveness and complete loss of the 31-036 click signature.
The most recent click chemistry studies to have been conducted were reactions
designed to ensure that TAMRA-azide and TAMRA-biotin-azide bind to the same targets
in cells (Figure 6.13 pg 70). As the addition of a large group such as biotin may have
affected the ability of the TAMRA-biotin-azide to access all the alkyne-tagged proteins (in
their native state) available to TAMRA-azide,160 these initial studies were key for verifying
that click reactions using TAMRA-biotin-azide would be similar to those with TAMRA-azide
in native conditions. In these experiments, I verified that TAMRA-biotin-azide was indeed
binding to the same targets in cells as assessed by a similar in-gel fluorescence click
signature. Furthermore, I demonstrated that TAMRA-biotin-azide reacted with the alkyne
tag of 31-036-bound p65. IKKβ was not used in this experiment due to difficulties
associated with purchasing IKKβ in a buffer solution that does not contain compounds
(glutathione and dithiothreitol) that will affect the reaction between 31-036 and the target
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cysteine residue of IKKβ. Moving forward we will use this trifunctional TAMRA-biotin-azide
to complete the mass spectrometry studies that have already been suggested.
Determining the form of IKKβ targeted by 13-197 and 25-4
We hypothesize that 13-197 and 25-4 inhibit IKKβ activity without inducing the
toxicities associated with previously reported IKKβ inhibitors by specifically targeting
activated IKKβ without binding resting, inactivated IKKβ. In this model (Figure 3.6 pg 32)
IKKβ would be briefly activated by TNF, allowing short activation of IKKβ prior to small
molecule binding. We hypothesize that this brief activation provides enough signaling
through the NF-κB pathway to allow proper immune functioning (data not shown).
However, the inhibition of activated IKKβ by these small molecules would inhibit sustained
activation of IKKβ. This selective inhibition of activated IKKβ appears to be sufficient to
drive death or reduce viability of cancer cells (Figure 5.9, 5.10, 5.11, 6.4, 6.5, 6.6, 6.7 on
pgs 50, 51, 53, 62, 63, 64, and 65, respectively and Table 1 pg 62).
To verify that 13-197 indeed inhibits a phosphorylated form of IKKβ, I have recently
identified IKKβ antibodies that can be used to immunoblot and immunoprecipitate
unphosphorylated and phosphorylated IKKβ. Using these antibodies, I will repeat the
experiment shown in Figure 5.5 (pg 47) but will also immunoprecipitate IKKβ at various
time points post-stimulation with TNF (0, 5, 10, 15, 30, 45, 50, 90 and 120 min poststimulation) and immunoblot lysate for both total and phosphorylated IKKβ and IκB. If
phosphorylated IKKβ is present at the time points where inhibition of IκB phosphorylation
by 13-197 is seen (90 and 120 min post-stimulation, for example) but little inhibition is
seen at earlier time points, we may further assert that 13-197 indeed inhibits
phosphorylated IKKβ. Furthermore, kinase and binding assays (see substrate binding
experiments on pg 106) may be performed with immunoprecipitated phosphorylated IKKβ
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to further demonstrate that 13-197 blocks phosphorylation of IκB by phosphorylated
IKKβ.
Analysis of the forms of IKKβ inhibited by 25-4 will be more straightforward. The
above experiment described for 13-197 can be performed with 25-4 though treatment with
the small molecule will occur following stimulation with TNF as 25-4 likely targets DNA
binding by p65 and will block resynthesis of IκB, leaving no substrate for IKKβ at late
time points. Additionally, click chemistry with 25-4 analog 31-036 will be performed with
lysates collected at the same time points post TNF stimulation as described for 13-197.
Pulldown with streptavidin beads will be performed following click chemistry with TAMRAbiotin-azide and pulled down protein will be resolved by SDS-PAGE and transferred to a
membrane. The membrane will be immunoprobed for total and phosphorylated IKKβ. If
31-036 preferentially targets phosphorylated IKKβ, phosphorylated IKKβ will be pulled
down in 31-036-treated lysates while nonphosphorylated IKKβ will not (will only see total
IKKβ band in lanes with phosphorylated IKKβ). Again, endogenous IKKβ can be
immunoprecipitated using anti-IKKβ antibody and kinase or IKKβ binding assays
(visualized following click chemistry between 31-036 and TAMRA-azide) can be
performed to demonstrate preferential inhibition of phosphorylated IKKβ by 25-4 and 31036. Furthermore, phosphorylated IKKβ can be confirmed as a target of 31-036 in the
mass spectrometry studies previously proposed for identifying the targets of 25-4 analog
31-036.
Polypharmacology
Drugs commonly interact with multiple targets in cells and although these off-target
interactions are generally associated with harmful side-effects, there is growing evidence
that drugs that interact with multiple targets may still, and in reality do, provide therapeutic
benefit. This emerging paradigm is termed polypharmacology and describes a drug that
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targets 1) multiple members within a single signaling pathway or 2) multiple proteins that
each play a role in a different signaling pathway, though these pathways may be
interconnected. Examples of polypharmacological agents include aspirin, which covalently
modifies at least 120 targets in cells and is used to treat a variety of indications.194, 195
Furthermore, the anticancer medications sunitinib, pazopanib, sorafinib and dasatinib are
known to inhibit multiple proteins. Not only do these drugs target multiple pathways and
thus multiple processes known to drive cancer, but they also prevent drug resistance as
they will still exert activity through their remaining targets even if one becomes resistant
to treatment.194, 196
With this in mind, though both 13-197 and 25-4 are known to target multiple
proteins, we are confident future work to identify additional binding targets of 13-197 and
25-4 and subsequent optimization of these small molecules using structure-based drug
design will reduce undesirable, off-target effects by these drugs. Furthermore, the ability
of these small molecules to target two proteins upstream of NF-κB-driven transcription
(IKKβ and MAP4K4 in the case of 13-197 and IKKβ and p65 in the case of 25-4) as well
as other targets possibly relevant to cancer (Nek3 for 13-197 and unknown targets of 254) may be quite beneficial for overall activity in cells. Again, future studies with the
compounds and their analogs will be required to test this.
Rational design of IKKβ inhibitors
In spite of the massive effort made by pharmaceutical companies to develop viable
inhibitors of IKKβ, no such inhibitor has been approved for clinical use for the treatment of
cancer. Nevertheless, cell- and animal-based studies continue to demonstrate the
anticancer effects of IKKβ inhibition. The work outlined in this dissertation supports the
hypothesis that IKKβ is indeed a viable target for anticancer research. By biasing our
studies around a small molecule that allows the transient activation of IKKβ (13-197) and
a targeting motif (-methylene--butyrolactone) of a natural product that inhibits IKKβ

114
without inducing severe toxicities, we were able to develop two small molecules that are
active against IKKβ in cancer cell lines. Furthermore, these small molecules have shown
promise in studies with clinically-approved therapeutics, again suggesting that IKKβ is a
desirable target for anticancer research. Most importantly, these small molecules reduced
tumor burden in mice without inducing toxicities, especially those associated with
previously described IKKβ inhibitors. Future studies in our lab will outline the mechanistic
basis for the non-toxic inhibition of IKKβ by these small molecules.
As new information regarding the structure of resting and phosphorylated IKKβ are
made available, structure-guided drug discovery efforts focused on IKKβ will likely lead to
the development of next-generation IKKβ inhibitors. These new small molecules, along
with the previously discovered IKKβ inhibitors, will allow drug discovery groups to perturb
and study the poorly-understood regulation of IKKβ’s activity by its complex members and
positive and negative regulators. These studies will provide valuable insights that will allow
researchers to develop targeted IKKβ inhibitors that inhibit diseased states of the kinase
that persist in cancer and other diseases without affecting the transient activation of IKKβ
that appears to be necessary for normal cellular functioning. Rational design of IKKβ
inhibitors will be key for targeting the protein without inducing toxicity.
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